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ABSTRACT 
STEVEN D. CAPPELL: Systematic Analysis of Essential Genes Reveals New 
Regulators of G Protein Signaling 
(Under the direction of Dr. Henrik G. Dohlman) 
Heterotrimeric G proteins are molecular switches that respond to a wide range of 
stimuli including light, neurotransmitters, small molecules and peptides.  Due to their role 
in a variety of physiological responses, it is no surprise that over 50% of drugs modulate 
G protein signaling pathways.  While many drugs function at the level of the G protein-
coupled receptor, downstream signaling components are increasingly being investigated 
as drug targets.  Therefore, discovery of new components and regulators will help 
identify new ways to exploit G protein-coupled signaling pathways for therapeutic utility. 
Previous attempts to systematically identify new components of G protein 
pathways have focused on genome-wide knockout screens including gene-deletion 
mutants.  However, these methods are inherently limited because they exclude the 
essential genes.  In this thesis, we present studies to identify new signaling components 
by systematically analyzing 870 essential genes using repressible-promoter strains.  
Specifically, we show that the SCFCdc4 E3 ubiquitin ligase complex regulates G protein 
turnover and catalyzes ubiquitination of the G protein α subunit, Gpa1.  Also, we 
demonstrate that Pik1, a phosphatidylinositol (PtdIns) 4-kinase, regulates the mitogen-
activated protein kinase (MAPK) cascade and helps maintain signaling fidelity.  These 
findings reveal the essential-genome as an untapped resource for identifying new 
components and regulators of signal transduction pathways.  Furthermore, work on this 
thesis has expanded our understanding of G protein signaling networks and could lead 
to future opportunities for drug discovery.  
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Organisms growing in complex environments are exposed to multiple chemical 
and physical stimuli.  The ability to interpret and respond to such stimuli is critical for a 
cell to survive in changing environments.  At the cellular level, external signals are 
transduced across the plasma membrane by a variety of cellular signaling networks.  
However, the most widely used networks are those coupled to heterotrimeric G proteins.  
Organisms as diverse as yeast and humans utilize G-protein coupled receptors 
(GPCRs) to respond to a wide range of stimuli including light, tastes, odors, 
neurotransmitters, and hormones (1-3).  Given their role in critical biological processes, 
perturbations of G protein signaling pathways are often associated with human disease 
(4).  Not surprisingly, G proteins and GPCRs have been extensively studied because of 
their potential importance as pharmacological targets.  In fact, over 50% of drugs 
currently on the market target GPCRs, thereby modulating G protein-coupled signaling 
pathways (5-7).  Notable examples include antidepressants such as Zoloft (sertraline 
hydrochloride), antipsychotics such as Zyprexa (olanzapine), and the asthma drug 
Singulair (montelukast).  While directly targeting GPCRs has been highly successful, 
efforts to find new drugs have focused on downstream modulators of G protein signaling 
(8-10).  Therefore, by studying proteins and signaling events downstream of receptor 
activation, it is possible to identify new drug targets in G protein signaling pathways. 
This thesis will focus on new regulators of G proteins and the signaling pathways 
they activate.  While many proteins are known to regulate G protein function, much is 
still unknown about other aspects of G protein signaling, such as protein turnover.  In 
this introductory chapter, special attention will be paid to known regulators of G protein 
signaling, how these regulators were originally identified, and recent advancements that 
allow for more sophisticated methods of studying G protein signaling pathways. 
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Heterotrimeric G proteins 
Cell surface receptors with seven-transmembrane domains couple to 
heterotrimeric guanine nucleotide binding proteins (G proteins), thereby linking the 
extracellular environment to the inside of the cell.  Heterotrimeric G proteins are 
comprised of α, β, and γ subunits and function as molecular switches (Figure 1.1).  In the 
absence of stimulus, the Gα subunit is bound to GDP and the obligate heterodimer Gβγ.  
Activation of the receptor by an extracellular ligand results in the exchange of GDP for 
GTP on the Gα subunit of the heterotrimer.  GTP-bound Gα undergoes conformational 
changes in three distinct switch regions that allow it to dissociate from the Gβγ dimer.  
Both Gα and Gβγ can then signal through effector proteins to elicit their downstream 
effects (11).  Inactivation of G proteins results from the slow intrinsic GTPase activity of 
Gα, hydrolyzing GTP to GDP (12).  After hydrolysis, GDP-bound Gα has lower affinity 
for effectors and a higher affinity for free Gβγ and thus the heterotrimeric complex 
reforms, terminating signaling.  To accelerate inactivation, G proteins are negatively 
regulated by a class of proteins known as regulators of G protein signaling (RGS) (13), 
which stabilize the transition state of GTP hydrolysis and function as GTPase 
accelerating proteins (GAPs) (14).   
Heterotrimeric G proteins are regulated by a number of accessory proteins.  In 
addition to receptors and RGS proteins, which activate and inactivate G proteins 
respectively, there are several other classes of proteins that modulate G protein function.  
First, guanine nucleotide dissociation inhibitors (GDIs) function to limit activation of the 
Gα subunit by inhibiting the release of GDP.  The most notable example is Gβγ, which 
functions as a GDI to reduce basal activation of Gα.  Also, the 19 amino acid GoLoco 
motif functions as a GDI on the Gαi/o class of G proteins (15), and is found on a number 
of proteins, including RGS12 (16).  A crystal structure of the GoLoco motif in complex 
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Figure 1.1 
 
Figure 1.1  The heterotrimeric G protein activation cycle. 
G protein-coupled receptors (GPCR) respond to extracellular ligands and 
activate heterotrimeric G proteins inside the cell.  When inactive, the Gα subunit is 
bound to GDP and the Gβγ dimer.  Upon ligand binding, the receptor functions as a 
guanine nucleotide exchange factor (GEF) allowing Gα to exchange GDP for GTP.  
GTP-bound Gα undergoes a conformational change and dissociates from Gβγ. Both 
subunits are then free to activate downstream effectors. Signaling is terminated by 
hydrolysis of GTP, a reaction that is catalyzed by GTPase accelerating proteins (GAP) 
such as the regulator of G protein signaling (RGS) family of proteins, which stabilize the 
transition state of the reaction.   
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with Gαi1-GDP revealed a direct interaction between three conserved residues of the 
GoLoco motif and the α- and β-phosphates of GDP.  This crystal structure indicated GDI 
activity is mediated by direct contact with GDP, preventing its release from Gα (17).  
Second, G protein activation can be modulated by non-receptor guanine nucleotide 
exchange factors (GEFs).  To date, several non-receptor GEFs have been identified 
such as Ric-8A (18), Arr4 (19), and GIV (20).  Similar to GPCRs, non-receptor GEFs 
accelerate the release of GDP on the Gα subunit, facilitating the binding of GTP, which 
is in excess in the cell.  However, unlike GPCRs, non-receptor GEFs typically cannot 
accelerate nucleotide exchange on the heterotrimeric complex.  They require dissociated 
Gα−GDP to accelerate GDP release.  This observation has led to the hypothesis that 
non-receptor GEFs work after receptor-driven activation and function to sustain signaling 
by promoting faster cycling of Gα (21).  Through a combination of GPCRs, RGS 
proteins, GDIs, and non-receptor GEFs, cells have the ability to fine-tune G protein 
signaling, suggesting all of these proteins could be exploited for therapeutic utility (8, 
22).  However, of the proteins listed, only drugs that target GPCRs have made it through 
clinical trials and into patients.  Thus, further efforts are needed to identify new proteins 
that regulate G protein signaling pathways in the hopes of finding better drug targets.   
Model systems for studying heterotrimeric G protein signaling 
The human genome encodes more than 700 GPCRs, 20 Gα subunits, 5 Gβ 
subunits, and 13 Gγ subunits.  Given this complexity, simpler model organisms have 
been extensively utilized to study fundamental principles of G protein signaling.  In the 
yeast S. cerevisiae, a single canonical heterotrimeric G protein signaling pathway 
regulates the process of cell mating.  In addition to having only one GPCR and G 
protein, there are several other reasons why yeast is an attractive model for studying G 
protein signaling.  First, most of the yeast components are highly conserved in humans.  
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In particular, the G protein (23) and mitogen-activated protein kinase (MAPK) 
components (24-26) are both structurally and functionally similar to their human 
counterparts (Figure 1.2).  Therefore, discoveries made in yeast will be applicable to 
human G protein signaling.  Second, the signaling events downstream of the receptor 
and G protein are well understood.  Pathway activation results in easily measured 
phenotypes including cell-cycle arrest, morphological changes, and new gene 
transcription.  Third, yeast has the ability to stably grow as a haploid, making it easy to 
identify recessive mutations.  Fourth, yeast readily undergo homologous recombination, 
making it easy to perform gene replacement and gene disruption at the genomic-scale.  
In fact, a gene-deletion strain has been made for nearly every non-essential gene in 
yeast (27) and a tetracycline-repressible strain has been made for nearly every essential 
gene (28).  This combination allows for unprecedented coverage when using genome-
wide screens to uncover novel signaling components.    
Yeast exist as one of two haploid mating types, MATa and MATα.  In the 
proximity of a member of the opposite mating type, the yeast cell will excrete a small 
polypeptide pheromone: MATa cells release a factor and MATα cells release α factor 
(29, 30).  The pheromones activate GPCRs on the cell surface eliciting a mating 
response consisting of transcriptional changes, polarized growth, and cell cycle arrest at 
the G1 phase, which ultimately results in the fusion of two haploid cells to produce one 
diploid cell (31). 
The pheromone response pathway has been extensively studied for over 40 
years, and is arguably the most well understood signaling pathway in any eukaryotic 
organism.  Many of the core components required to transmit signaling from the plasma 
membrane to the nucleus have been identified and characterized.  The yeast 
pheromone receptor, Ste2, couples to a heterotrimeric G protein made up of Gpa1Gα (32- 
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Figure 1.2 
 
Figure 1.2  MAPK signaling pathways are conserved from yeast to humans. 
(A) Human MAPK pathways. (B) Yeast MAPK pathways. Most components of 
yeast MAPK pathways have homologs in humans.  Fus3 is homologous to Erk2 (green); 
Kss1 is homologous to Erk1 (Red); Hog1 is homologous to p38 (Blue).  Thus, 
discoveries in yeast are likely to lead to discoveries in humans.  G protein-coupled 
receptor (GPCR); receptor tyrosine kinase (RTK).  
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34), Ste4Gβ, and Ste18Gγ (35) (Figure 1.3).  Pheromone binding to Ste2 promotes 
exchange of GDP for GTP on Gpa1.  GTP-bound Gpa1 then dissociates from the 
Ste4/18 dimer.  Dissociated Ste4/18 activates the MAPK cascade (36) comprised of 
Ste20, Ste11 (37, 38), Ste7 (39), the partially redundant MAPKs Fus3 and Kss1 (40), 
and the MAPK scaffold Ste5 (41-43).  Active Fus3 then phosphorylates the transcription 
factor Ste12 (44, 45), which regulates the expression of genes necessary for proper 
mating responses (46-49).   
The pheromone response pathway - Discovery of the components that 
comprise the pheromone pathway is the result of two key advancements in the field of 
biology.  The first breakthrough came in the 1970’s when two labs used classical genetic 
techniques to identify mutations that conveyed sterility to yeast.  In 1974, Mackay and 
Manney published two papers in which they irradiated yeast cells with an ultraviolet light 
to induce random mutations in the yeast genome (50, 51).  The mutagenized yeast were 
then mixed with members of the opposite mating type and spread on selective agar 
medium.  The experiment was designed so that only unmated, sterile cells would grow 
on the selective medium.  Genetic analysis of the sterile colonies identified 20 genes 
thought to be involved in pheromone signaling.  Mackay and Manney designated these 
genes with the symbol ste (STErile) and numbered them in the order that they were 
characterized.  
While Mackay and Manney were irradiating yeast to identify genes involved in 
mating, Lee Hartwell was using temperature-sensitive mutants to identify genes involved 
in the cell cycle (52-56), an endeavor that would eventually win him the Nobel Prize in 
Medicine in 2001 (57).  Once Hartwell had identified many of the genes involved in the 
cell division cycle (CDC), he shifted his attention to the pheromone pathway and its 
ability to induce cell-cycle arrest (58).  Hartwell randomly mutagenized yeast using 
ethylmethane sulfonate and selected for colonies that mated at 22oC but not at 34oC.  
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Figure 1.3 
 
Figure 1.3  The yeast mating response pathway. 
Haploid yeast respond to mating pheromones through a canonical heterotrimeric 
G protein-coupled signaling pathway.  Pheromone causes the dissociation of GTP-
bound Gpa1 and the Gβγ dimer comprised of Ste4 and Ste18.  Free Ste4/18 coordinates 
the activation of the MAPK cascade by binding the MAPK scaffold Ste5 and activating 
the small G protein Cdc42.  This leads to the phosphorylation of Fus3, which mainly 
activates two effectors: Ste12 and Far1.  Ste12 is a transcription factor that regulates 
mating-specific genes and Far1 is a cyclin-dependent kinase inhibitor that causes cell 
cycle arrest in the G1 phase. 
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Using temperature-sensitive mutants allowed Hartwell to conduct complementation 
studies and thus achieve a greater understanding of the function of each ste gene.  
Hartwell was able to narrow down Mackay and Manney’s list of genes in the pheromone 
pathway from 20 to 8, including the major pathway components Ste2, Ste4, Ste5, Ste7, 
Ste11, and Ste12.   
Examining these early studies with the benefit of hindsight reveals the authors 
made some insightful conclusions about their data.  For example, Hartwell was able to 
determine that Ste2 is specific only to MATa cells, and likely encodes the pheromone 
receptor, without any knowledge of the sequence of the gene or the protein it encodes.   
Such insights, obtained only through simple genetic techniques, underscore the power of 
yeast genetics and illustrate why the pheromone pathway is now one of the most well-
characterized signaling pathways in eukaryotes. 
Early studies of the pheromone pathway identified the key genes absolutely 
required to transmit signaling across the plasma membrane to elicit intracellular effects.  
However, we now know that some genes function in the pheromone pathway but are not 
absolutely required for mating.  These genes, such as SST2, FUS3, and KSS1, were 
missed by both Mackay and Manney’s and Hartwell’s screens.  While these simple 
genetic techniques were quite successful, increasingly sophisticated technologies are 
required to identify genes that are not necessary for pheromone signaling but rather fine-
tune signaling.  
 While the genes required for pheromone signaling were identified relatively 
quickly, discovering the proteins they encoded and their biochemical functions would 
take many years.  From 1980-1995, many different labs worked on individual ste genes.  
For example, Whiteway et al. found that Ste4 encodes the Gβ subunit of the yeast 
heterotrimeric G protein (35).  Additional research identified genes with roles in the 
pheromone pathway that did not yield a sterile phenotype when mutated.  For example, 
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the MAP kinase Fus3 was identified in a screen for mutants defective in cell fusion after 
mating (40), the Gα subunit Gpa1 was identified as a gene homologous to mammalian 
Gα subunits (23, 34), and the RGS protein Sst2 was identified in a screen for mutants 
super-sensitive to pheromone (59).  Despite the success in characterizing known 
components, the rapid pace of discovery of new components and regulators of the 
pheromone response pathway was beginning to subside in the mid-1990’s.   
The second major breakthrough came in 1996, when the yeast genome was 
completely sequenced by a worldwide collaboration (60).  It was the first completely 
sequenced genome of a eukaryote and ushered in a new age of conducting science.  
Prior to this, approximately 1000 yeast genes were known (61), but the sequence 
incredibly identified almost 6,000 open-reading frames (ORFs).  The addition of almost 
5,000 new genes greatly increased the opportunity for discovering new signaling 
components.  However, given the complexity of studying 6,000 genes, new tools and 
techniques would be required to study an organism at the genomic-scale.   
In the years following the sequencing of the yeast genome, an international 
consortium was formed to systematically disrupt every ORF in the yeast genome.  In 
2000, the Saccharomyces Genome Deletion Project released the Yeast Knock-Out 
(YKO) deletion collection, which included almost 82% of all yeast genes (27, 62).  While 
Manney, Hartwell, and others relied on random mutagenesis, the YKO collection allowed 
for the systematic analysis of almost every gene to identify new components and 
regulators of G protein signaling.  For the first time, research could be conducted on the 
genomic-scale, assaying the function of every gene simultaneously, instead of relying on 
the variable process of generating random mutations or the time consuming process of 
studying one gene at a time.   
Our lab utilized the YKO collection to identify genes required for proper 
pheromone signaling and answer a long-standing question about the role of the yeast 
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Gα subunit.  In the yeast mating pathway pathway, the signal generated by pheromone 
stimulation is mostly propagated by Gβγ effectors (63, 64).  For many years, it was 
thought that Gpa1 functions solely to sequester Gβγ, and prevent it from activating 
downstream effectors.  Therefore, Gpa1 was considered a negative regulator of the 
pathway.  In support of this model, deletion of Gpa1 results in constitutive activation of 
the pheromone pathway and permanent cell-cycle arrest.  However, given the role of 
human Gα subunits in activating downstream effectors, it was speculated that the yeast 
Gα subunit may also activate downstream effecters.  In 2006, Slessareva et al. sought to 
identify novel effectors of Gpa1 by screening the YKO collection for deletion strains that 
block signaling by a constitutively active Gpa1QL mutant.  Using this systematic 
approach, they found that GTP-bound Gpa1 activates the phosphatidylinositol (PtdIns) 
3-Kinase Vps34 at the endosome, resulting in increased PtdIns 3-P production, 
translocation of signaling components to the endosome, and enhanced MAPK activation 
(65).  Thus, Gpa1 has a positive role in signaling and can, in fact, activate effectors.  
Given that Vps34 or its human homolog had never been implicated in G protein 
signaling, it is unlikely that a more directed, hypothesis-driven approach would have 
identified it as a Gα effector.  Therefore, the systematic approach utilized by Slessareva 
et al. was instrumental in discovering the first new component of the pheromone 
pathway in almost 8 years (66).  Despite the yeast pheromone pathway being mapped 
out in incredible detail over the previous 35 years, this result demonstrated that more 
signaling components are still waiting to be discovered using systematic screening 
methods.  
Essential genes 
One of the outcomes of the yeast Genome Deletion Project was the realization 
that 18% of yeast genes are essential for growth.  Genes involved in cellular processes 
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required for cell viability such as cell division, DNA replication, and cytoskeletal 
rearrangements tend to be essential (27, 62).  Interestingly, essential genes are more 
highly conserved than the non-essential genes; 38% of essential genes have a human 
ortholog compared to only 20% of non-essential genes (67).  Thus, any discoveries 
made while studying yeast essential genes are more likely to translate to humans.  
Additionally, their role in cell viability makes them attractive drug targets for diseases 
such as cancer.   
Despite the benefits of studying essential genes, they have remained poorly 
characterized.  This is due primarily to the fact that essential genes are incredibly difficult 
to study.  They cannot be permanently deleted in haploid cells and mutations that alter 
their function or enzymatic properties tend to be lethal.  Classical genetic techniques, 
such as random mutagenesis employed by Mackay and Manney, are not suited for 
identifying essential genes.  For example, the yeast Gα subunit GPA1 is essential, 
because when it is deleted, the Gβγ dimer is free to activate signaling, and induces 
permanent cell-cycle arrest, terminating growth.  GPA1 was not originally identified in 
screens conducted by Mackay and Manney or Hartwell, and its role in the pheromone 
pathway escaped detection until 1987, when it was identified due to its similarity to 
human Gα subunits (23, 34).  The fact that the G protein alpha subunit, arguably the 
most important component of the pheromone pathway, could not be identified by random 
mutagenesis screens underscores the limitation of previous techniques to identify novel 
signaling components, and highlights the need for more sophisticated screening 
methods in order to study the role of essential genes.   
Temperature-sensitive mutants - The best way to identify the function of a 
given gene is to delete it and look for altered cellular behavior or morphology.  Since an 
essential gene cannot be stably deleted, conditional mutants are required.  The most 
common method of generating a conditional mutant is to create a temperature-sensitive 
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(ts) mutant (68).  A plasmid containing the wild-type gene is randomly mutagenized and 
transformed into a strain lacking the same gene.  For essential genes, the mutagenized 
plasmid must be transformed at the same time the genomic allele is deleted.  Once 
colonies form, they are patched onto two different plates, one placed at 25oC and the 
other placed at 37oC.  The ts mutants are those that grow at 25oC, the permissive 
temperature, but not at 37oC, the restrictive temperature.  Mutations that convey 
temperature-sensitivity usually alter protein stability and result in unfolded protein at the 
restrictive temperature.  Thus, the protein can be rapidly knocked-down by growing the 
cells at elevated temperatures.  The main drawback to this technique however, is that 
the exact function of the randomly generated mutation is not known (69).  For example, 
the mutation could only cause local instability of a particular domain within the protein, 
disrupting some functions but retaining others.  This could cause unforeseen effects 
such as making a dominant-negative.  Alternatively, the mutations could be overly 
effective, resulting in low activity at the permissive temperature, and rapid loss of protein 
function at the restrictive temperature.  This could alter cell viability or induce cell stress 
pathways that could alter the experimental outcome.  Thus, experimental conditions 
cannot be properly controlled if the function of the mutation is not fully understood.  
Furthermore, this method is time consuming, results can vary from gene to gene, and it 
is not suited for high-throughput systematic screens.   
Alternative methods have been developed to generate ts alleles in a more 
systematic manner and remove the variability and uncertainty that comes with 
generating random mutants.  In 1986, Alexander Varshavsky discovered that the half-life 
of a given protein is determined by the amino-acid composition of the N-terminus.  
Proteins with amino-terminal residues such as arginine or lysine are degraded more 
quickly than proteins with amino-terminal residues such as glycine or alanine, a 
phenomenon called the “N-end rule” (70).  Subsequently, it was found that proteins 
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degraded by the N-end rule are ubiquitinated on a lysine close to the N-terminus and 
degraded by the proteasome (71, 72).  
Varshavsky wanted to use the N-end rule as a tool to generate a ts N-degron 
sequence.  To this end, he found a mutant form of the mouse protein dihydrofolate 
reductase (DHFR) that contains a destabilizing arginine residue at its N-terminus, yet is 
long-lived in yeast.  Using the standard methods described above, Dohmen et al. 
created a ts mutant of DHFR (DHFRts) that is stable at the permissive temperature but is 
rapidly degraded by the N-end rule at the restrictive temperature.  They reasoned that 
fusion of DHFRts to the N-terminus of other proteins should convey temperature-
sensitivity to that protein.  To test this hypothesis, they fused DHFRts to the essential 
gene CDC28 and created a protein (Cdc28td) that was also stable at 25oC but rapidly 
degraded at 37oC.  Thus, DHFRts can serve as a temperature-inducible degron (td) 
sequence when fused to another gene (73).  This strategy offers several improvements 
over the traditional method of generating ts mutants.  First, the td method does not 
typically alter the function of the protein of interest because many proteins can tolerate 
modification of the N-terminus.  In contrast, random destabilizing mutations are likely to 
affect protein function.  Second, degradation of the td sequence is rapid and predictable, 
whereas ts alleles can cause only partial disruption of protein stability, resulting in slow 
or incomplete degradation of the protein of interest.  Thus, the td method normalizes the 
time required for degradation between two proteins.  Finally, by simply fusing the td 
sequence to the protein of interest, one can bypass the need for an exhaustive search 
for ts alleles generated by random mutagenesis.  This makes the td method preferable 
when conducting large-scale systematic screens.  For example, Kanemaki et al. fused 
the td sequence to half of the essential genes with an unknown function to determine if 
any have a role in regulating the cell cycle (74).  This experiment would not be possible if 
ts alleles had to be independently generated, one at a time.  
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  Despite having many benefits for studying essential genes, ts and td strains 
have several major drawbacks.  The most obvious limitation to using both methods is the 
requirement for growth at sub-optimal temperatures that could have unintended effects.  
At 37oC, enzymes will exhibit altered kinetics, cells will divide more quickly, off-target 
genes will likely be de-stabilized, and cellular stress pathways will be activated, all of 
which could affect the outcome of the experiment.  For example, growth at 37oC causes 
a 50% reduction in MAPK activation in response to pheromone in wild-type cells (75).  
Therefore, any phenotype caused by a temperature-sensitive allele may be masked by 
the effect of non-physiological temperatures on normal cell growth.  A second limitation 
is that both techniques require altering the open-reading frame of the protein, which 
could affect normal protein function.  As mentioned above, random mutations can affect 
protein function in a number of unknown and undesired ways.  Fusion of the td 
sequence to proteins helps eliminate most of this uncertainty, but protein function can 
still be affected.  The heat-inducible N-degron sequence is actually a 21 kDa protein, 
which could interfere with normal protein folding, protein-protein interactions, and 
localization.  Furthermore, some proteins cannot tolerate alterations to their N-terminus. 
For example, Gpa1 is mysristoylated and palmitoylated at its N-terminus and both 
modifications are required for proper localization to the plasma membrane (76-79).  
Disruption of either modification by adding additional residues to the N-terminus results 
in mislocalized Gpa1, constitutive activation of the pheromone pathway, and permanent 
cell cycle arrest.  Likewise, transmembrane proteins do not tolerate alteration of their N-
termini.  Therefore, ts and td mutants are not suitable for studying a significant portion of 
essential genes.  
Regulatable-promoter strains - Conditional mutants can also be generated by 
using a regulatable-promoter.  Such an approach is an attractive alternative to 
temperature-sensitive mutants because it allows for tight control of gene expression 
17 
without changing the open-reading frame, protein function, or the temperature at which 
cells are grown.  In yeast, there are several regulatable-promoters that can be used, and 
selecting the correct promoter requires a detailed understanding of the advantages and 
disadvantages of each.   
The most widely used regulatable-promoter is the GAL1-10 promoter, which can 
be induced up to 1000-fold by galactose (80, 81).  This makes the GAL promoter useful 
when overexpression is required.  In addition, gene repression can be achieved by the 
removal of galactose from the growth medium.  The main drawback of the GAL promoter 
is that it requires changing the carbon source from glucose to galactose, which alters cell 
metabolism.  The presence of glucose in the growth medium actively represses the 
GAL1-10 promoter (82).  Thus, transcriptional induction can be delayed as much as 1 hr 
while the cells metabolize any glucose still remaining in the medium.  To counterbalance 
this delay, cells can be grown in medium containing the alternative carbon source 
raffinose, which does not repress the GAL1-10 promoter.  However, cellular growth is 
not optimal in raffinose-containing medium (83).  Regardless, the required changes in 
carbon source affect cell metabolism and growth-rate, complicating the interpretation of 
any phenotypes that may arise upon overexpression of the gene of interest.  Therefore, 
the GAL1-10 promoter should be used with caution.    
 An alternative solution is the MET3 promoter, which is repressed by methionine 
(84).  Removal of exogenous methionine results in low-level induction of genes under 
the control of the MET3 promoter.  This method is useful when overexpression is not 
desired.    However, low gene induction and changes in the nutritional composition of the 
growth medium limit its usefulness in many applications (85).  The copper-inducible 
promoter CUP1 has slightly higher induction ratios than MET3, but gene expression in 
the absence of copper can be quite high (86-88).  Thus, the CUP1 promoter cannot be 
as tightly regulated as the MET3 and GAL1-10 promoters.  Furthermore, at high enough 
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concentrations, copper can be lethal, and the introduction of copper into the growth 
medium at concentrations sufficient for CUP1 induction could have pleiotropic effects on 
the cellular stress response (89).  All three of these regulatable-promoters, GAL1-10, 
MET3, and CUP1, were designed from endogenous promoter systems and thus all 
suffer from the same disadvantage; they require nutritional changes to the growth 
medium.  A better solution would incorporate a promoter not induced by nutrients, but 
rather a substance that is relatively inert in yeast.   
The tetracycline-resistance operon of Escherichia coli provides a system of 
regulating gene transcription in yeast that relies on a non-endogenous control element 
(90).  In E. coli, the transcription of resistance-mediating genes is inhibited by the 
tetracycline repressor (TetR) protein (91).  In the presence of the antibiotics tetracycline, 
TetR can no longer bind to the tet operon promoter sequence (tetO) and transcriptional 
repression is alleviated (91).  Thus, tetracycline induces gene expression.  In 1992, 
Gossen and Bujard adapted this system so that it could be used in other organisms (90) 
(Figure 1.4).  They fused TetR to the viral transcription factor virion protein 16 (VP16) 
(92), to create a tetracycline-controlled transactivator (tTA).  They also adapted the tetO 
sequence by fusing it to the minimal promoter sequence for VP16 (TetO).  In the 
absence of tetracycline, the tTA binds with high affinity to TetO, and transcription is 
induced by VP16 up to 1000-fold.  In the presence of tetracycline, the tTA falls off the 
TetO and transcription is terminated.  Thus, tetracycline inhibits gene expression.  This 
system is often referred to as “Tet-Off.”  
Of the regulatable-promoters outlined above, the tetracycline-repressible 
promoter system is the most attractive for several reasons.  First, the affinity of 
tetracycline or the more stable analog doxycycline for TetR is very high (~1nM) (93).  
Therefore only small doses are required to achieve sufficient gene repression.  Second, 
tetracycline and doxycycline have limited physiological effects on organisms other than 
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Figure 1.4 
 
Figure 1.4  The tetracycline-repressible promoter system. 
The tetracycline-repressible promoter system requires two components.  First, a 
fusion of the tetracycline repressor (TetR) protein and virion protein 16 (VP16) is 
expressed under the control of a constitutive CMV promoter.  This fusion protein is 
called the tetracycline transactivator (tTA).  Second, the promoter of the gene of interest 
is replaced with seven repeats of the tetracycline operon (TetO) promoter sequence. In 
the absence of doxycycline, the tTA binds the TetO and drives expression of the gene of 
interest.  When added to the growth medium, doxycycline binds the tTA and causes it to 
fall off the TetO and transcription is terminated.  
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bacteria, including yeast and humans, and no changes in the nutritional content of the 
growth medium are required.  Thus, unlike the other regulatable promoters GAL1-10, 
MET3, CUP1, the Tet-Off promoter system is unlikely to produce pleiotropic effects on 
cell physiology.  Third, the binding interaction between tTA and TetO is highly specific so 
off-target gene induction is unlikely (90).  Fourth, the Tet-Off system has a very high 
induction ratio (91).  In the absence of doxycycline gene expression is very high, while in 
the presence of even low concentrations of doxycycline gene expression is extremely 
low.  
The major drawback of the Tet-Off system, and indeed all regulatable promoter 
systems, is that mRNA production can be rapidly inhibited while protein levels decrease 
much more slowly.  Depending on the natural rate of decay for a given protein, the 
emergence of phenotypes due to gene depletion can be significantly, and sometimes 
unpredictably, delayed.  This caveat must be taken into account when characterizing a 
large number of proteins whose half-lives may vary considerably.  Regardless, the Tet-
Off system remains the most attractive approach for characterizing large numbers of 
genes, because TetO strains can be easily generated and only minimal changes to 
growth conditions are required.  
Since the sequencing of the yeast genome in 1996, all the non-essential genes 
have been systematically deleted, but the essential genes have eluded systematic 
analysis.  In a recent effort to overcome this deficit, Hughes and colleagues generated a 
library of tetracycline-repressible promoter strains for 602 of the 1,100 yeast essential 
genes (28).  They incorporated the tTA originally developed by Gossen and Bujard (90) 
into the yeast genome and then systematically replaced the promoter of each essential 
gene with seven repeats of the TetO cassette (TetO7).  In the years since, the library has 
expanded to include over 900 essential genes.  This powerful new tool allows for the 
systematic analysis of almost all (~80%) the yeast essential genes.  Indeed, Mnaimneh 
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et al. analyzed the original 602 TetO7-strains using four phenotypic assays including 
cellular morphology, cell size, growth rates under 15 different conditions, and 
transcriptional profiles using microarrays (28).  This approach helped assign functions to 
several previously uncharacterized genes and identify new genes involved in ribosome 
biogenesis and mitochondrial import.  The Hughes TetO7 library has also been used to 
identify essential genes involved in the cell division cycle (94), mitochondrial 
morphogenesis (95), and tombusvirus RNA recombination (96).  In Chapter II, I describe 
a systematic screen of the essential genes using the TetO7 library to identify new 
regulators of the yeast pheromone response pathway.   
Ubiquitin-proteasome system 
 Efficient protein degradation is essential for many cellular processes such as 
progression through the cell cycle (97), the DNA damage response (98), and regulation 
of metabolic pathways (99).  Some proteins undergo normal turnover to maintain steady-
state levels while others must be rapidly degraded to switch cellular mechanisms on or 
off.  In either case, the 26S proteasome functions to degrade the majority of proteins in 
the cytoplasm and the nucleus (100, 101).  Proteins destined for proteolysis by the 26S 
proteasome are marked by the covalent attachment of multi-ubiquitin chains, allowing 
the 26S proteasome to recognize which proteins should be degraded.  Tight control of 
the ubiquitination process is required to target the correct proteins for degradation and 
prevent the unnecessary degradation of the incorrect proteins.  Not surprisingly, 
deregulation of the ubiquitin-proteasome system is often associated with human 
diseases such as cancer (102) and Parkinson’s disease (103).  
 Ubiquitin is an 8 kDa protein (104, 105) that is attached to substrates through the 
processive action of E1, E2, and E3 enzymes (106).  Ubiquitin is activated for 
attachment to substrates by the E1 ubiquitin-activating enzyme (107).  In an ATP-
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dependent reaction, a thioester bond is formed between the active site cysteine of the 
E1 and the C-terminal carboxyl group of ubiquitin (108).  Then, ubiquitin is transferred to 
the active site cysteine of an E2 ubiquitin-conjugating enzyme via a 
trans(thio)esterification reaction (106).  Finally, an E3 ligase is required to transfer 
ubiquitin either directly or indirectly from the E2 to an internal lysine residue on the 
substrate, resulting in an isopeptide bond between the lysine residue and the C-terminal 
glycine of ubiquitin.  E3 ligases directly bind substrates and therefore confer substrate 
specificity to the ubiquitination machinery (109).  Given that ubiquitin contains seven 
internal lysines, it also can serve as a substrate for ubiquitination, resulting in multi-
ubiquitin chains (72). 
 Substrate proteins can either be mono- or poly-ubiquitinated and each 
modification results in a different fate.  Monoubiquitination is defined as the attachment 
of three or less ubiquitins to a substrate (110).  Typically, transmembrane proteins or 
proteins localized to membranes are monoubiquitinated, which results in their 
internalization by endocytosis and subsequent degradation by the lysosome or vacuole 
(111).  Polyubiquitination is defined as the attachment of a multi-ubiquitin chain 
consisting of four or more ubiquitins (112).  Chain elongation can occur through any of 
the seven lysines on ubiquitin, and linkages through different lysines can have different 
effects.  Chains made of K48-linked ubiquitin are the most common, and target proteins 
for degradation by the 26S proteasome (112).  Linkages by other lysines can have 
proteolysis-independent functions (113).  Most notably, K63-linked polyubiquitin chains 
have a role in signal transduction and can activate kinases.  For example, upon 
stimulation of cells with proinflammatory cytokines, the protein TRAF6 is modified with 
K63-linked ubiquitin chains.  Proteins containing ubiquitin-binding domains specific for 
K63-linked chains are recruited to TRAF6, which results in the activation of IkappaB 
kinase (IKK) (114).  Distinct E3 ligases are required to generate ubiquitin chains through 
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different lysines.  Likewise, distinct E3 ligases are required for mono- versus poly-
ubiquitination (115).   
 Typically, organisms such as yeast and humans have only one E1 enzyme that is 
responsible for activating the entire cellular pool of ubiquitin (116, 117).  There are 
slightly more E2 enzymes.  Yeast have 13 E2 enzymes, but each is capable of coupling 
with multiple E3 ligases.  E3 ligases are by far the most diverse; humans have ~500 and 
yeast have ~40.  Across all species, more than 1000 E3 ligases have been identified 
(115).  Considering E3 ligases provide substrate specificity to the ubiquitination reaction, 
it is no surprise they are by far the most diverse component of the ubiquitin machinery.  
There are three main subfamilies of E3 ubiquitin ligases: homologous to E6-AP carboxyl 
terminus (HECT) domain-containing E3s, single-subunit really interesting new gene 
(RING) domain-containing E3s, and multi-subunit RING domain-containing E3s.   
 HECT domain E3s – The HECT domain is a conserved 350 amino acid 
sequence that was originally discovered in the E6-associated protein (E6-AP) (118).  
Five yeast genes are classified as HECT domain-containing E3 ligases due to their 
similarity to E6-AP.  Aside from the conserved sequence, the ubiquitination reaction 
catalyzed by HECT domain-containing E3 ligases further distinguishes them from RING 
domain-containing E3s.  The HECT domain first binds an E2 conjugating enzyme and 
ubiquitin is transferred from the E2 to the active site cysteine of the HECT domain (115).  
Through an additional protein-protein interaction domain, HECT E3s bind the substrate 
and directly catalyze the transfer of ubiquitin to an internal lysine residue on the 
substrate.  HECT E3s contain a number of different protein-protein interaction domains 
but the most common is the WW domain, which is capable of binding phosphoserine 
and phosphothreonine residues (119) .  The most well characterized HECT E3 ligase in 
yeast is Rsp5 (118).  Rsp5 contains a C2 domain for binding phospholipids at 
membranes and a WW domain for binding substrates that contain the consensus 
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sequence Proline-Proline-X-Tyrosine (120).    
 Ubiquitination of substrates by HECT E3s can be regulated by several different 
mechanisms.  Many HECT E3s are constitutively active and are regulated by an adapter 
protein that recruits a ubiquitin-charged E2 activating enzyme to the E3-substrate 
complex (121).  Such is the case with the human E3 ligase Smurf1 and its substrate the 
TGF-β receptor (122).  The adapter protein Smad7 binds both Smurf1 and the TGF-β 
receptor and then recruits ubiquitin-charged UbcH7E2 to initiate ubiquitination.  
Alternatively, constitutively active HECT E3s can be associated with a deubiquitinating 
enzyme (DUB) which functions to remove ubiquitin from substrates.  Rsp5 associates 
with Ubp2, a ubiquitin-specific protease, that functions to “edit” substrate ubiquitination 
by Rsp5.  Rsp5 has been shown to polyubiquitinate some substrates and 
monoubiquitinate others (123).  It is hypothesized that Ubp2 functions to partially 
degrade multi-ubiquitin chains to produce monoubiquitinated substrates.  However, it is 
not known how Ubp2 recognizes which proteins should be monoubiquitinated.  Other 
HECT E3 ligases are basally inactive and can be activated by phosphorylation (121).  
The human E3 Itch is inactive due to intra-molecular interactions between its WW 
domain and HECT domain (124).  Phosphorylation by the MAP kinase JNK1 disrupts 
this intra-molecular interaction and activates Itch (125).  These examples demonstrate 
that HECT E3s have acquired a variety of different mechanisms, some quite elegant, to 
tightly regulate protein ubiquitination.  As will be discussed below, RING domain-
containing E3 ligases are typically regulated via only one mechanism.   
 RING domain E3s – The RING domain was originally identified as a conserved 
zinc-binding motif in the human protein Really Interesting New Gene (RING) 1 due to its 
similarity to other known zinc fingers.  Since their discovery, over 200 proteins have 
been found to contain RING domains.  RING domains are comprised of repeating 
histidine and cysteine residues that allow binding of two zinc molecules (121).  While the 
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exact primary sequence is not highly conserved, the spacing of the two zinc molecules is 
invariant in almost all RING domains, indicating they play a particularly important role in 
regulating function.  For years, the exact function of the RING domain was unknown and 
it was thought that they were DNA binding motifs, like other zinc fingers.  However, in 
1999 three independent groups found proteins with RING domains bound E2 ubiquitin-
conjugating enzymes, suggesting RING domains play an important role in ubiquitination 
(126-128).  Subsequent discoveries revealed these RING domain-containing proteins 
were actually E3 ubiquitin ligases.  This revelation had a huge impact in the 
ubiquitination field since it meant that the more than 200 proteins with RING domains 
were all E3 ligases.  
 RING E3s are catalytically distinct from HECT E3s.  Whereas HECT E3s have an 
active site cysteine and catalyze ubiquitination, RING E3s have no enzymatic activity 
and function solely as scaffolds.  They function to bring the substrate and the ubiquitin-
conjugated E2 sufficiently close to each other for efficient transfer of ubiquitin to the 
substrate (115).  This lack of enzymatic activity is most likely why the RING E3s escaped 
detection for almost a decade, and their initial characterization actually triggered a fierce 
debate in the ubiquitination field as to whether they should in fact be called E3 “ligases.”  
As such, a protein with a RING domain is often referred to as simply an “E3”.   
 There are two different types of RING E3s: single-subunit and multi-subunit.  
Single-subunit RING E3s, such as the human proteins c-Cbl (129) and Mdm2 (130), 
contain both a RING domain and a substrate-binding domain.  Multi-subunit RING E3s 
are comprised of multiple proteins that, together, form a functional E3.  Typically, one 
protein in the complex contains a RING domain and binds the E2 while another protein 
contains a substrate-binding domain (131).  Other proteins in the complex function as 
scaffolds, adapters, or regulatory subunits.  The two major types of multi-subunit RING 
E3s are the Skp1-cullin-F-box (SCF) complex and the anaphase promoting complex 
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(APC) (reviewed in (131-133)).  For this introduction, the main focus will be the SCF 
complex since it is discussed further in Chapter II of this thesis. 
 SCF complex – The SCF complex is a heterotetrameric complex that functions 
to bind both a substrate and an E2 conjugating-enzyme to facilitate ubiquitination.  The 
SCF complex was first identified in yeast and was named after three of its key 
components: Skp1, Cullin, and F-box protein (134, 135).  The F-box protein conveys 
substrate specificity to the complex through a substrate-binding domain, and is denoted 
in superscript to differentiate SCF complexes (e.g SCFCdc4 where Cdc4 is the F-box).  
Typically, several different F-box proteins can couple to the same SCF complex, greatly 
increasing the variety and number of different proteins that can be ubiquitinated by the 
SCF.  Regulation of SCF-mediated ubiquitination is generally through the 
phosphorylation of target proteins (131).  Almost all the substrates identified so far must 
be phosphorylated before they can bind the F-box protein (135).  This provides the cell 
with a simple mechanism to regulate which proteins should be ubiquitinated by the SCF 
complex.   
 In yeast, the most well-studied SCF complex is SCFCdc4 and it is comprised of 
Cdc4, Skp1, Cdc53, and Roc1 and couples with the E2 enzyme Cdc34.  These four 
essential components form a scaffold that holds the substrate and E2 enzyme close 
enough to allow the transfer of ubiquitin.  The F-box protein, Cdc4, binds substrates, 
Cdc53 and Roc1 bind the E2 conjugating enzyme, and Skp1 is an adapter protein that 
binds both Cdc4 and Cdc53, linking the entire complex (Figure 1.5).  
 The SCFCdc4 was discovered through a series of papers that slowly identified the 
function of all the components of the complex.  CDC4, CDC53, and CDC34 were 
identified in screens for mutants with defects in the cell division cycle (136, 137).  
Subsequently, all three were found to be required for the degradation of the G1/S phase 
checkpoint protein Sic1 (136, 137), indicating they may play a role in regulating Sic1 
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Figure 1.5 
 
Figure 1.5  The SCF E3 ubiquitin ligase complex. 
The SCF complex is an E3 ubiquitin ligase and is comprised of four essential 
components. A protein that contains a RING domain binds the E2 ubiquitin-conjugating 
enzyme. The F-box protein functions as the substrate receptor and typically binds 
phosphorylated substrates.  Skp1 is an adapter that links the F-box protein to the rest of 
the complex.  The cullin functions as a scaffold and organizes the complex by binding 
multiple components.  In yeast, the SCF is comprised of the yeast proteins Cdc4, Skp1, 
Cdc53, and Roc1 and couples to the E2 enzyme Cdc34.   
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turnover.  At the time, it was known that Cdc34 was an E2 ubiquitin-conjugating enzyme, 
further supporting this hypothesis (138).  Cdc53 was also found to be part of a recently 
identified protein family called Cullins which were involved in protein turnover (139).  
However, the exact role of Cdc4 and Cdc53 in Sic1 ubiquitination and degradation was 
unclear.  Further complicating the model, SKP1 was identified in a screen for genes that 
suppress cdc4ts mutants when overexpressed.  It was then shown that skp1ts mutants 
were also defective in Sic1 degradation and that Skp1 binds Cdc4 at a conserved motif 
called an F-box (140).  Thus, Cdc4, Cdc53, and Skp1 were thought to form a multi-
protein complex that along with Cdc34 is required for ubiquitination of Sic1.  To 
definitively test this hypothesis, Skowyra et al. and Feldman et al. expressed Cdc4, 
Cdc53, and Skp1 from insect cells and showed they formed a functional E3 ubiquitin 
ligase, that along with Cdc34 purified from bacteria, was capable of ubiquitinating 
phosphorylated Sic1 in vitro (134, 135).  Interestingly, Skowyra et al. also showed that 
another protein containing an F-box domain, Grr1, was capable of forming an SCF 
complex with Skp1 and Cdc53.  SCFGrr1 was unable to bind Sic1, but was able to bind a 
different SCF substrate, Cln1 (135).  These data indicate F-box proteins are 
interchangeable substrate receptors and, by coupling to different F-box proteins, the 
SCF can target a wide range of proteins for ubiquitination (141).   
 As mentioned above, SCF complexes contain four different proteins, yet Skowyra 
et al. and Feldman et al. expressed only three proteins in insect cells to form a functional 
SCF ligase (134, 135).  The fourth protein in the SCF complex was eventually 
discovered a few years after their papers were published.  Three independent groups 
identified Roc1 as a protein that co-purified with Cdc53, was required for Sic1 
degradation, and contained a RING domain (142-144).  Coincidentally, this discovery 
was made around the same time that RING domains were found to be E3 ligases that 
bind E2 enzymes (126-128).  This led to the obvious hypothesis that Roc1 must be a 
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missing link between the core SCF components Cdc4, Cdc53, and Skp1 and the E2 
enzyme Cdc34.  Indeed, when Roc1 was added to Cdc4, Cdc53, and Skp1 purified from 
insect cells, Sic1 ubiquitination was greatly enhanced (144).  Later, it was determined 
that by expressing Cdc4, Cdc53, and Skp1 in insect cells, Skowyra et al. and Feldman et 
al. inadvertently co-purified the insect homolog of Roc1, thus forming a functional SCF 
complex (131).  This highlights the fact that SCF components are highly conserved 
across species, and discoveries made in model organisms such as yeast are likely to 
yield similar results in humans.  
 Typically, the SCF is regulated through its interaction with substrates.  Given the 
F-box protein is the substrate receptor for the complex, it is the most functionally 
relevant subunit.  All F-box proteins contain a short conserved ~50 amino acid domain 
called an F-box that mediates binding to Skp1.  The F-box was first identified as a 
shared motif between Cyclin F and Cdc4 (140).  Since then, over 400 F-box proteins (18 
in yeast) have been identified (145, 146).  F-box proteins also contain a substrate-
binding domain and a short linker that connects the F-box to the substrate-binding 
domain, which has been implicated in regulating protein turnover (147) and dimerization 
(148).  F-box proteins are divided up into three main families based on their substrate 
binding domains which can be seven WD40 repeats (FBXW), multiple leucine-rich 
repeats (FBXL), or a unique binding domain (FBXO) (146).   Cdc4, the prototype F-box 
protein, contains seven WD repeats (crystal structures reveal a possible eighth cryptic 
WD40 repeat) and is highly conserved (149).  The human homolog of Cdc4 is Fbw7 
(150, 151).  While F-box proteins contain a diverse array of substrate-binding domains, 
they all seem to selectively bind phosphorylated substrates.  Thus, despite evolutionary 
divergence of the F-box protein structure, they have maintained a conserved regulatory 
mechanism, suggesting that control of protein ubiquitination by phosphorylation conveys 
an evolutionary advantage. 
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 Since the discovery of the SCFCdc4 over 13 years ago, much effort has gone into 
identifying all of its substrates.  Only six have been identified, including Sic1 (152).  This 
lack in progress is mostly due to the difficulty in identifying protein substrates of E3 
ligases.  Typically, one must demonstrate both a functional and a physical interaction 
with the E3 before a protein can be considered a substrate.  However, demonstrating a 
physical interaction can be very difficult since interactions are often very weak, substrate 
levels in the cell are usually low, and when interactions occur they lead to rapid 
ubiquitination and degradation of the substrate (152, 153).  Furthermore, most 
substrates must first be phosphorylated before they can bind the SCF.  Unless the 
cellular conditions that promote substrate phosphorylation are known, no physical 
interactions will be detected.  Thus, the identification of SCF substrates remains a high 
priority.    
Gα  ubiquitination 
Gα proteins undergo a variety of different post-translational modifications 
including i) myristoylation, ii) palmitoylation, iii) ADP-ribosylation, iv) phosphorylation, 
and v) ubiquitination.  These diverse modifications regulate cellular localization, the 
ability to interact with other proteins, GTP hydrolysis, and GDP release, and play a 
critical role in the regulation of G protein signaling.  Of all these post-translational 
modifications however, G protein ubiquitination is the least studied.   
The first evidence of G protein ubiquitination came in 1994 when it was shown 
that the yeast G protein, Gpa1, was degraded by the N-end rule (154).  In 1996, Obin et 
al. purified a ubiquitinated protein out of retinal rod outer segments that had the same 
molecular weight as Gt (155).  Human Gαi3 was shown to be degraded in HEK293 cells 
in a proteasomal-dependent manner, and it was shown that overexpression of a putative 
E3 ubiquitin ligase enhanced degradation.  However, direct evidence of Gα 
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ubiquitination was lacking in this report (156).  Recently, more convincing evidence of G 
protein ubiquitination in humans has emerged.  Nagai et al. was able to detect 
ubiquitinated Gαs in HEK293 cells by using the proteasomal inhibitor MG132.  
Furthermore, they showed that the protein Ric-8B (a homolog of Ric-8A which functions 
as a non-receptor GEF) binds Gαs and prevents its ubiquitination and subsequent 
degradation (157).  While the details of human G protein ubiquitination are still emerging, 
it is clear that ubiquitination does play a role in regulating Gα abundance in several 
different organisms.  Ubiquitination of the yeast Gα subunit, Gpa1, is by far the most 
studied (154, 158-161).  As further evidence of human G protein ubiquitination is 
gathered, Gpa1 is likely to serve as a model for studying both the regulation of G protein 
ubiquitination and its role in G protein-mediated signaling pathways.    
 Gpa1 is one of only a few proteins that is known to be both mono- and poly-
ubiquitinated.  Consistent with its localization at the plasma membrane, Gpa1 is 
monoubiquitinated, endocytosed, and delivered to the vacuole for degradation (159).  
Rsp5, a HECT E3, is necessary and sufficient for Gpa1 monoubiquitination both in vivo 
and in vitro (160).  Interestingly, Rsp5 also monoubiquitinates the α factor receptor Ste2 
and mediates receptor internalization after pheromone stimulation (162, 163).  The fact 
that Gpa1 and Ste2 are targeted for internalization by the same enzyme indicates Gpa1 
and Ste2 monoubiquitination may both be required for desensitization.  However, it is not 
currently known how Gpa1 monoubiquitination by Rsp5 is regulated.  While Ste2 
ubiquitination is stimulated by pheromone treatment, Gpa1 monoubiquitination is not 
(159, 162).  Thus, the exact role of Gpa1 monoubiquitination is unknown and is an active 
area of research.  
 Gpa1 is also polyubiquitinated and degraded by the 26S proteasome (159).   
Mass spectrometry analysis revealed that Gpa1 is modified with ubiquitin on K165 (158).  
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Polyubiquitination of Gpa1 can be blocked by deletion of the ubiquitinated subdomain 
(residues 128-236) and results in a dampened pheromone response (159).  Such a 
phenotype is consistent with overexpression of Gpa1 which functions to sequester Gβγ 
and inhibit signaling (164).  However, contrary to this phenotype, blocking poly-
ubiquitination of Gpa1 did not alter total cellular abundance of Gpa1 as measured by 
western blotting (159).  These data indicate that polyubiquitination may regulate specific 
subpopulations of Gpa1.  Thus, while total cellular Gpa1 levels are unchanged, specific 
subpopulations of Gpa1 could be elevated, resulting in dampened pheromone signaling.  
Further study of Gpa1 polyubiquitination is needed to fully understand its role in 
regulating G protein signaling.  
 The E3 ligase that mediates Gpa1 polyubiquitination is unknown, but it is distinct 
from Rsp5.  Why yeast require two different modes of ubiquitinating Gpa1 is not well 
understood, but identifying the E3 ligase involved in polyubiquitination could reveal 
important differences in the regulation of mono- vs poly-ubiquitination.  Furthermore, E3 
ligases involved in yeast G protein ubiquitination are likely to be conserved in humans 
and could be useful drug targets.   
Phosphatidylinositol kinases 
Phosphatidylinositol (PtdIns) is a component of cell membranes and has a role in 
regulating many cell signaling pathways.  PtdIns has both polar and non-polar groups 
allowing it associate with both the plasma membrane and cytosolic proteins (165).  It is 
comprised of a glycerol backbone, two fatty acids, and a phosphate group attached to an 
inositol head group (Figure 1.6).  The inositol head group has five hydroxyls and each 
are capable of being phosphorylated by specific PtdIns kinases to produce 
phosphoinositides (166).  Yeast have six such kinases and are capable of producing five 
distinct derivatives of PtdIns, each with its own cellular function (165).  Typically,
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Figure 1.6 
 
Figure 1.6  Phosphatidylinositol is phosphorylated by lipid kinases 
Phosphatidylinositol (PtdIns) is an amphiphatic lipid that associates with both 
non-polar lipid membranes and the cytosol.  Phosphorylated derivatives of PtdIns are 
called phosphoinositides and function as membrane anchors for many proteins. They 
are comprised of two non-polar fatty acid chains, a glycerol backbone, and a polar 
inositol headgroup.  Inositol can be phosphorylated by a number of lipid kinases to 
produce different PtdIns derivatives.  For example, Stt4 and Pik1 phosphorylate PtdIns 
at the 4 position to make PtdIns 4-P.  Phosphatases such as Sac1 and Sjl2 catalyze the 
reverse reaction and remove the phosphorylation.   
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 phosphoinositides can regulate cell signaling pathways in one of two ways.  First, they 
can serve as a substrate for phospholipases, which cleave PtdIns and produce the 
second messengers inositol phosphate (IP) and diacyglyercol (DAG) (167, 168).  
Second, phosphoinositides can bind cytosolic proteins altering either their localization or 
activity.  A variety of phospholipid-binding domains have been identified so far including 
the pleckstrin homology (PH) domain, phox homology (PX) domain, epsin N-terminal 
homology (ENTH) domain, and Fab1p/YOTB/Vac1p/EEA1 (FYVE) domain (169).  Each 
domain can have a different specificity for phosphorylated subspecies.  For example, the 
PX domain of Bem3 binds only to PtdIns 3-P while the PX domain from Bem1 binds 
PtdIns 3-P and PtdIns 4-P (170).  Such differences allow for the regulation of only a 
subset of lipid-binding domains by a given PtdIns kinase.    
PtdIns have long been known to play an important role in G protein signaling 
(171-173).  In mammals, Gq activates phospholipase C (PLC) which cleaves PtdIns 
3,4,5-P3 to produce IP3 and DAG (174).  Both of these second messengers then trigger 
the release of intracellular calcium stores from the endoplasmic reticulum.  More recently 
however, a new role for PtdIns in G protein signaling was identified in yeast.  Slessareva 
et al. found that GTP-bound Gpa1 activates the PtdIns 3-kinase Vps34 and stimulates 
the production of PtdIns 3-P at the endosome (65).  PtdIns 3-P then recruits the PX 
domain-containing protein Bem1 to the endosome and is required for full activation of 
the MAPK Fus3.  This new discovery indicates PtdIns may have a larger role in 
pheromone signaling than was previously recognized.   
Thesis summary 
 The pheromone pathway has served as a model system for studying 
heterotrimeric G proteins for many years.  It all started with Mackay, Manney, and 
Hartwell who discovered the first sterile genes in yeast (50, 51, 58).  Since then, the 
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yeast pheromone pathway has been one of the most intensely studied signaling 
pathways in all eukaryotes.  Insights made in yeast have often led to discoveries in 
humans.  Relevant examples include the RGS protein Sst2 (13, 59, 175), the MAPK 
scaffold Ste5 (176), and the F-box protein Cdc4 (150).  At the time research began on 
this thesis, systematic screens to identify new components of the pheromone pathway 
had attained impressive coverage, including deletion strains representing almost 5,000 
genes (177).  Thus after more than 30 years of research, almost 80% of genes had been 
assayed for activity in the pheromone pathway.  The last 20% however, has proven the 
most difficult to study since they are essential for cell growth and survival.  The essential 
genes represent one of the last frontiers of yeast genetics and are a virtually untapped 
resource for identifying new components of signaling pathways coupled to heterotrimeric 
G proteins.  For my thesis research, I intended to identify new components of the yeast 
pheromone pathway by systematically screening the essential genes, and to finally 
achieve near 100% coverage of the yeast genome.  I undertook this challenge in the 
hopes that discovering new regulators of G protein signaling would lead to a better 
understanding of human G protein signaling and perhaps to the development of new 
therapies to treat G protein-related diseases.   
The remainder of this thesis is divided into 3 chapters.  In Chapter II, “Systematic 
screen of essential genes reveals important regulators of G protein signaling,” I present 
a genome-scale screen of the TetO7 promoter library, including the design and validation 
of the screening method.  Also in this chapter, I characterize several essential genes that 
were identified in the screen, with special attention paid to the SCFCdc4 complex and its 
role in regulating G protein ubiquitination.  In Chapter III, “Selective regulation of MAP 
kinase signaling by an endomembrane phosphatidylinositol 4-kinase,” I compare and 
contrast the role of two PtdIns 4-kinases, Pik1 and Stt4, in regulating the pheromone 
pathway and reveal a unique role for Pik1 in regulating parallel MAP kinase pathways.  
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Finally, in Chapter IV, “Conclusions and general discussion,” I discuss the broad impact 
of these findings and speculate on the future direction of the field.  
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Summary 
The yeast pheromone pathway consists of a canonical heterotrimeric G protein 
and MAP kinase cascade.  To identify new signaling components we systematically 
evaluated 870 essential genes using a library of repressible-promoter strains. 
Quantitative transcription-reporter and MAPK activity assays were used to identify 
strains that exhibit altered pheromone sensitivity.  Of the 92 newly identified essential 
genes required for proper G protein signaling, those involved with protein degradation 
were most highly-represented.  Included in this group are members of the SCF (Skp-
Cullin-F-Box) ubiquitin ligase complex.  Further genetic and biochemical analysis reveals 
that SCFCdc4 acts together with the Cdc34 ubiquitin conjugating enzyme at the level of 
the G protein, promotes degradation of the G protein α subunit, Gpa1, in vivo and 
catalyzes Gpa1 ubiquitination in vitro.  These new insights to the G protein signaling 
network reveal the essential-genome as an untapped resource for identifying new 
components and regulators of signal transduction pathways.  
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Introduction 
The budding yeast Saccharomyces cerevisiae is an established model for 
investigating fundamental biological processes including cell division, cell growth, and 
intracellular communication.  One unique attribute of the yeast system is the availability 
of several thousand isogenic gene-deletion strains, which allows for unbiased genome-
scale analysis of cellular functions (27).  However, of the approximately 6,000 genes in 
the yeast genome, nearly 1,100 are essential for viability and difficult to study using 
standard gene-deletion mutants.  This limitation has led to a poor understanding of a 
substantial fraction of the yeast genome (28).  Notably, these essential genes are more 
likely to have a human ortholog, as compared with non-essential genes (38% vs. 20%) 
(67).  Here we describe the identification of new components and new regulators of the 
G protein signaling apparatus.  Our approach was to conduct a systematic analysis of 
the “essential genome”, identify components required for efficient signal transduction, 
and establish their mode of action. 
In yeast, a canonical heterotrimeric G protein signaling pathway regulates the 
process of cell mating.  Yeast exists as one of two haploid cell types, a and α, that 
secrete peptide pheromones (a factor and α factor).  These ligands bind to cell surface 
receptors, consequently promoting new gene transcription, morphological changes, cell 
cycle arrest, cell fusion, and the creation of an a/α diploid cell (178). 
As in other G protein pathways, agonist stimulation of the α factor receptor (Ste2) 
promotes exchange of GDP for GTP on the G protein α subunit (Gpa1).  GTP-bound Gα 
undergoes conformational changes and dissociates from the Gβγ subunit dimer 
(Ste4/18).  Dissociated Gβγ can then signal through effector proteins including a 
mitogen-activated protein kinase (MAPK) cascade (Ste20, Ste11, Ste7, and Fus3).  
Inactivation of G protein signaling results from the slow intrinsic GTPase activity of Gα, 
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hydrolyzing GTP to GDP, and the re-association of Gα and Gβγ subunits.  GTP 
hydrolysis is further accelerated by the RGS (Regulator of G protein Signaling) protein 
Sst2.  Therefore, Gpa1 functions primarily to sequester Gβγ in the absence of receptor 
stimulation (178).   
Many components of the yeast pheromone pathway were identified genetically, 
by isolating mutants that exhibit a mating-deficient (sterile) phenotype (58).  Recent 
efforts to identify new components of G protein signaling have employed more 
systematic, genome-scale approaches (65).  For example, a library of gene-deletion 
strains (representing almost all of the non-essential genes) was used to identify direct 
effectors of Gα signaling.  Consequently, it was shown that Gpa1Gα modulates 
pheromone signaling through a direct interaction with phosphatidylinositol (PtdIns) 3-
kinase, resulting in elevated production of the second messenger PtdIns 3-P (65).   
While the non-essential genes have been thoroughly studied, the essential genes 
are inherently less tractable and have therefore been poorly characterized.  Previous 
approaches to investigating essential gene function have included the isolation of 
temperature-sensitive (ts) alleles, or fusion to a heat-inducible degron sequence (73, 
74).  However, the use of temperature-sensitive alleles requires growth at sub-optimal 
temperatures, and introduces destabilizing mutations that could alter enzyme function or 
protein-protein interactions.  Recently a new resource for studying essential genes has 
been developed.  Hughes and colleagues have constructed a library of repressible-
promoter strains representing 870 of the yeast essential genes (28).  These strains 
employ the tetracycline-regulatable promoter (TetO7 promoter) system, allowing for 
precise control of gene expression, with no change in protein sequence or function.  This 
TetO7 promoter library has been used previously to identify new components of the cell 
division cycle (94), translation, and mitochondria import machinery (28).  However, the 
role of essential genes in signal transduction has not been explored in any systematic 
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manner.   
While signal transduction networks, such as those mediated by heterotrimeric G 
proteins, are not typically thought of as essential for cell viability, they can share 
components with essential processes such as control of cytoskeletal rearrangements 
and the cell division cycle (178).  In fact, GPA1 is an essential gene because when it is 
deleted, Gβγ is free to activate downstream effectors resulting in permanent cell cycle 
arrest (34).   
Here, we systematically characterized 870 essential genes for participation in the 
yeast G protein signaling pathway.  Our results show that proper G protein signaling 
requires the Cdc34 E2 ubiquitin conjugating enzyme and the SCFCdc4 E3 ubiquitin ligase 
(134, 135).  Ubiquitin ligases, such as the SCF, promote covalent modification of specific 
substrate proteins with ubiquitin, which can, in turn, target them for degradation by the 
26S proteasome (131).  Previous work has showed that Cdc34 and the SCF complex 
are involved in regulating the cell cycle and the mating-associated cell cycle arrest (135, 
179).  Here we show that SCF also regulates signal initiation, through ubiquitination of 
the G protein α subunit.  More generally, these findings reveal considerable overlap 
among genes required for cell viability and signal propagation. 
Results 
Screen of essential genes for new regulators of G protein signaling  
To identify new regulators of G protein signaling, we monitored the pheromone 
response in 870 TetO7 promoter strains.  This strain collection represents nearly all 
genes essential for viability.  Pathway activation was measured initially using a 
pheromone-inducible promoter from the FUS1 gene fused to the β-galactosidase (lacZ) 
gene.  To validate this approach, we tested the effects of inactivation of two essential 
genes known to function in the pheromone response pathway: GPA1 (34) and CDC42 
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(180).  GPA1 encodes a negative regulator of the pheromone pathway that functions to 
sequester Gβγ, and thereby prevents it from activating effectors.  As expected, 
doxycycline treatment of the TetO7-GPA1 strain resulted in constitutive activation of the 
pathway, and a higher dose of doxycycline exacerbated this effect (Figure 2.1 A).  
Conversely, CDC42 encodes a positive regulator required for full activation of the 
signaling cascade.  Doxycycline treatment of the TetO7-CDC42 strain resulted in 
complete loss of the pheromone response (Figure 2.1 B).  As expected, treatment of the 
TetO7 Wild-Type strain with doxycycline had no effect (Figure 2.1 C).  These results 
validate our screening method and demonstrate that the reporter assay is sufficiently 
sensitive to identify bona fide signaling components. 
The 870 TetO7 strains were next arrayed in a 96-well format and transformed 
with the FUS1-lacZ reporter.  Since gene product depletion varies depending on mRNA 
and protein half-life, we treated each strain with two doses of doxycycline (10 ng/mL and 
100 ng/mL) for 15hrs.  Each strain was then exposed to a range of six pheromone 
concentrations and β-galactosidase activity was measured using a spectrofluorometer.  
During the screening process, 61 essential genes repeatedly failed to either transform 
with the reporter plasmid or grow to a suitable cell density (A600nm = 0.8) required to 
conduct the reporter assay, and were not tested.   
After the initial rounds of screening, we identified 92 genes required for normal 
pheromone response as measured by our transcriptional reporter (Figure 2.2).  By using 
a highly specific reporter assay, we were assured that components of the mating 
pathway would be identified.  However we excluded an additional 97 genes likely to 
have global effects on transcription and translation.  The list of excluded genes is 
comprised of those involved in mRNA production, protein synthesis, DNA replication, 
RNA processing, or ribosome biogenesis.   
We classified our hits by functional category using Gene Ontology (GO)   
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Figure 2.1 
 
Figure 2.1  Validation of the TetO7 promoter essential gene screen. 
(A) Transcriptional activation (β-galactosidase activity) in response to α factor 
treatment was measured spectrofluorometrically in TetO7-GPA1 cells treated with 
doxycycline (Dox, 10 ng/mL and 100 ng/mL) or untreated control. Cells were 
transformed with a plasmid containing the pheromone-inducible reporter FUS1-lacZ. 
Data were analyzed by non-linear regression (sigmoidal-dose response, variable slope) 
using GraphPad Prism software. Results are the mean ± S.E. for three individual 
experiments each performed in triplicate.  (B) TetO7-CDC42 cells treated as in (A).  (C) 
TetO7-WT cells treated as in (A).  (D) Percentage of essential genes associated with the 
indicated GO Process.  (E) Percentage of essential gene hits associated with the 
indicated GO Process.  (F) Fold-enrichment of hits compared to all essential genes for 
each GO Process. 
44 
Figure 2.2 
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Figure 2.2  Phenotype clustering analysis. 
Gene hits were analyzed by Cluster 3.0 software based on maximum response, 
EC50, and basal activity normalized to the untreated control and converted to Log2. 
Gene similarity was calculated using Pearson correlation (uncentered correlation) and 
clusters were generated using centroid linkage. Clustering data was visualized by Java 
TreeView (v 1.1.3). Genes were labeled by their involvement in the indicated GO 
Process. 
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annotations generated by Osprey, whereby each gene was classified according to one 
of 30 GO processes.  When compared with all essential genes, our pheromone pathway 
hits were enriched for the following GO processes: protein degradation, cell cycle, 
protein transport, and phosphorylation (compare Figures 2.1 D and E).  Interestingly, 
genes involved in protein degradation were enriched 3-fold, by far the most highly 
represented group of functionally degradation were related genes (Figure 2.1F).   
In order to further prioritize our investigations, we generated an interaction map 
using the Osprey Network Visualization System (181), which incorporates known 
physical and genetic interactions from the Biological General Repository for Interaction 
Datasets (BioGRID) (182) (Figure 2.3).  We found several previously known interactions 
between pheromone pathway components and genes identified in our screen.  In 
particular, genes involved in cell organization and biogenesis (dark blue), protein 
transport (green), and protein degradation (orange) were highly connected to known 
pheromone pathway components.  We also used hierarchical clustering to organize 
genes into phenotypically similar groups based on changes in the maximal response, 
EC50, and basal activity (Figure 2.2).  We found that genes involved with protein 
degradation tended to cluster more closely than genes involved in other cellular 
processes such as metabolism, cell organization and biogenesis.  Given that genes 
involved in protein degradation were (i) over-represented in our screen, (ii) highly 
connected with known pathway components, and (iii) clustered more closely than any 
other functional group, we reasoned they must play a particularly important role in 
regulating G protein signaling.   
Screen validation 
Based on the above analysis, we selected six genes deemed likely to participate 
in cell signaling (Table 2.1).  MPS1 is the yeast ortholog of mammalian TKK (183), and 
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Figure 2.3 
 
Figure 2.3  Many of the hits from the essential-gene screen have known 
interactions with pheromone pathway components. 
The Osprey Network Visualization System software was used to generate an 
interaction network based on known genetic and physical interactions from BioGRID. 
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Table 2.1  Selected essential genes required for proper pheromone signaling    
Systematic 
Namea 
Standard 
Name Functionb 
Plasmid 
Rescue 
α factor Max 
Responsec,d 
α factor 
LogEC50c,d,e 
YDL028C MPS1 Dual-specific kinase; 
required for spindle 
checkpoint function 
Yes 178.7% ± 5.6% 
 
-5.71 ± 0.04 
 
YLR305C STT4 Phosphatidylinositol-
4-kinase; involved in 
the Pkc1 pathway 
Yes 44.8% ± 0.7% 
 
-6.10 ± 0.04 
 
YNL267W PIK1f Phosphatidylinositol-
4-kinase; may 
control cytokinesis 
through actin 
cytoskeleton 
Yes 88.3% ± 4.9% 
 
-5.82 ± 0.05 
 
YFL009W CDC4 F-Box protein; 
component of the 
SCF ubiquitin ligase 
Yes 46.1% ± 3.1% 
 
-5.40 ± 0.03 
 
YDR054C CDC34 E2 ubiquitin 
conjugating enzyme; 
component of the 
SCF ubiquitin ligase 
Yes 6.2% ± 0.2% 
 
-5.98 ± 0.05 
 
YDL132W CDC53 Cullin; component of 
the SCF ubiquitin 
ligase 
Not 
Done 
36.1% ± 1.9% 
 
-5.59 ± 0.06 
 
aThe essential genes PMA1 and SLN1 were confirmed but were not characterized further. 
bSaccharomyces Genome Database (www.yeastgenome.org). 
cFUS1 reporter transcription was measured in the indicated TetO7 strains treated with 
doxycycline or untreated control (average ± SEM). 
dTranscriptional response with α factor pheromone; α factor Max Response and LogEC50 data 
derived from nonlinear regression analysis (sigmoidal dose-response). 
eLogEC50 for TetO7 Wild-Type strain is -5.60 ± 0.01 M 
fShowed 4x increase in basal activity when treated with doxycycline. 
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is known to encode a dual-specificity kinase (184).  According to our hierarchical 
analysis it was the only gene that failed to cluster with any of the other 91 hits.  We 
speculate that Mps1 phosphorylates some component of the pheromone pathway.  We 
also selected for further consideration two PtdIns 4-kinases, STT4 and PIK1 (185, 186).  
Recently, components of the PtdIns 3-kinase, Vps15 and Vps34, were shown to bind 
directly to Gα and to be required for full activation of the pheromone signaling pathway 
(65).  Given this precedent, we postulated a broad role for mono-phosphorylated 
inositides in G protein signaling.  Validation of STT4 and PIK1 involvement in G protein 
signaling would strengthen the proposed model.  Among genes involved in protein 
degradation, we were particularly interested in CDC4, CDC34, and CDC53 because they 
encode proteins that either form (CDC53, CDC4) or function with (CDC34) the SCFCdc4 
ubiquitin ligase complex (134, 135).  The Cdc34/SCF family of ubiquitin ligases regulates 
a variety of proteins, in most cases promoting their degradation by the proteasome.  
Among SCFCdc4 targets are proteins that play key roles in the regulation of cell growth 
and division, and the mating-associated cell cycle arrest.  However, we were interested 
in determining a role of SCFCdc4 in regulating components of the G protein-coupled 
signaling cascade.   
The six TetO7 strains described above were re-transformed with the FUS1-lacZ 
reporter and re-tested individually using a broader range of pheromone concentrations, 
as well as a higher dose of doxycycline (10 µg/mL).  Testing individual strains in this 
manner confirmed results obtained by the high-throughput screening method.  For 
further validation, we transformed each TetO7 strain with a single-copy plasmid 
containing the absent wild-type gene, and showed this restored proper signaling (Table 
2.1). 
Transcriptional reporter assays are susceptible to false positives by proteins 
affecting overall gene expression.  To determine if any of the six components have 
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global effects on transcription or translation, we used a dual-reporter assay containing 
red fluorescent protein (RFP) under the control of a constitutive promoter (ADH1-RFP) 
and green fluorescent protein (GFP) under the control of a pheromone-responsive 
promoter (FUS1-GFP).  None of the six genes exhibited any change in RFP abundance, 
despite clear differences in GFP expression.  Investigation of five other randomly-
selected genes revealed three that alter RFP as well as GFP expression (Figure 2.4).  
Thus each of the six genes of interest regulates pheromone signaling specifically and 
not general gene transcription (Table 2.1).   
Analysis of pathway regulation by the newly identified essential genes 
Information from dose-response curves can be used to infer function.  For 
example, a gene mutation leading to an increase in maximal response typically indicates 
a negative role in signaling.  Knockdown of five genes, CDC4, CDC34, CDC53, STT4 
and PIK1, dampened the pheromone response (Figures 2.5 B-F), indicating a positive 
role in signaling.  Conversely, knockdown of MPS1 resulted in an increase in maximal 
activation (Figure 2.5 G), indicating a negative role in signaling.  Knockdown of PIK1 
resulted in substantial pathway activity even in the absence of pheromone addition 
(Figure 2.5 F).  These findings indicate that PIK1 (or its catalytic product PtdIns 4-P) 
serves to suppress basal signaling. 
To further define the function of each candidate gene, we measured pathway 
activity upstream of transcriptional regulation.  Phosphorylation of the MAPK is a 
prerequisite for transcription of pheromone-responsive genes.  Therefore we measured 
MAPK phosphorylation using an antibody that recognizes the dually-phosphorylated, 
fully-activated form of Fus3 and the partially redundant MAPK Kss1.  Compared to the 
TetO7 wild-type control strain (Figure 2.5 A), knockdown of CDC4, CDC34, CDC53, 
STT4, or PIK1 resulted in a decrease in Fus3 phosphorylation (Figures 2.5 B-F) in 
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Figure 2.4 
 
Figure 2.4  Hits from the essential-gene screen regulate G protein signaling 
upstream of translation. 
(A-L) The indicated TetO7 strains expressing the pRS315 AR/FG dual reporter 
plasmid were treated with 10 µg/mL doxycycline for 15 hrs and 3 µM α factor for 30min. 
Cell lysates were probed with GFP and RFP antibodies. Five additional strains, TetO7-
RIO2, TetO7-KIC1, TetO7-SSY1, TetO7-PMA1 and TetO7-SLN1, were also tested. 
Strains representing RIO2, KIC1, and SSY1 exhibited changes in RFP expression. 
Strains representing PMA1 and SLN1 showed no changes in RFP expression but were 
not considered further. 
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Figure 2.5 
 
Figure 2.5  Verification of the roles of selected essential genes in pheromone 
signaling.  
(A-G) The indicated essential genes were chosen for further validation and 
analysis. TetO7 strains expressing FUS1-lacZ were treated with 10 µg/mL doxycycline 
for 15 hrs and exposed to the indicated concentrations of α factor for 90 min. Below 
each pheromone dose-response curve is a corresponding immunoblot probed using 
phospho-p42/44 (P-Fus3, P-Kss1) or G6PDH (load control) antibodies. TetO7 strains 
were treated with 10 µg/mL doxycycline for 15 hrs and then 3 µM α factor for 30min. 
Results are the mean ± S.E. (n=5).  
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relation to total Fus3 levels (Figure 2.6).  Conversely, knockdown of MPS1 resulted in an 
increase in Fus3 activation (Figure 2.5 G).  Thus the changes in Fus3 phosphorylation 
mirror the changes in β-galactosidase activity reported above.  These results confirm a 
role for each gene in pheromone pathway regulation, and indicate they all function at a 
point upstream of the MAPK.   
Most genes involved in the pheromone response pathway regulate 
phosphorylation of both Fus3 and Kss1 in tandem.  Interestingly, doxycycline treatment 
of both TetO7-PIK1 and TetO7-STT4 strains resulted in a reduction of Fus3 but not Kss1 
activity (Figures 2.5 E and F).  Selective regulation of Fus3 has only been observed for a 
small number of gene deletion mutants, but this list includes the Fus3-binding protein 
Ste5 (176, 187) as well as the PtdIns 3-kinase Vps34 and its binding partner Vps15 (65).  
Pik1 and Stt4 are both PtdIns 4-kinases, but are present at different subcellular 
locations: Stt4 at the plasma membrane (188) and Pik1 at the Golgi and the nucleus 
(189).  Taken together, these findings reveal a possible role for mono-phosphorylated 
inositides in Fus3 signaling.   
SCFCdc4 regulates the pheromone pathway upstream of Ste4Gβ 
Of the essential genes found to regulate pheromone signaling, we were 
particularly interested in those that promote protein degradation.  As noted above, genes 
involved in degradation were enriched almost 3-fold compared to all the essential genes.  
Moreover they were clustered more closely than any other functional group in the 
hierarchical analysis.  Among the genes identified in our screen, CDC4, CDC34, and 
CDC53 encode components of the Skp1, Cullin, F-box protein (SCF)-type ubiquitin 
ligase (134, 135).  When treated with doxycycline, the TetO7-CDC4, TetO7-CDC34, and 
TetO7-CDC53 strains all exhibited a significant decrease in the maximal response to 
pheromone as well as diminished MAPK activation (Figures 2.5 B-D).  The similarity of 
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Figure 2.6 
 
Figure 2.6  Knock-down of essential genes affects Fus3 activation.  
(A-G) The indicated TetO7 strains were treated with 10µg/mL doxycycline for 15 
hrs and 3 µM α factor for 30 min. Cell lysates were probed with phospho-p42/44 (P-
Fus3, P-Kss1) and Fus3 antibodies. Bands were quantified by densitometry and the ratio 
of P-Fus3:Fus3 is shown below each immunoblot. Results are the mean ± S.E. (n=3). 
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the responses of these strains, and the fact that the affected proteins exist as a complex 
in cells, suggests the SCFCdc4 has a particularly important role in signal regulation.   
While each component of the SCF is necessary for ubiquitin-ligase function, the 
F-box protein, Cdc4, binds directly to the substrate and therefore defines substrate 
specificity of the SCF complex.  For this reason we focused further efforts on 
characterizing the role of Cdc4.  To narrow our search for Cdc4 substrates we activated 
the pathway at several points downstream of the pheromone receptor.  First, we over-
expressed the constitutively active STE11-4 mutant (190).  STE11 encodes the MAPK 
kinase kinase (MAPKKK) that phosphorylates Ste7, which in turn phosphorylates and 
activates Fus3 and Kss1.  TetO7-CDC4 cells expressing STE11-4 triggered MAPK 
phosphorylation in the absence of pheromone.  However, doxycycline treatment of these 
cells had no effect on Fus3 activity, in contrast to the reduction seen in pheromone-
stimulated cells (Figure 2.7 A).  These results indicate that SCFCdc4 acts on a protein 
component that is upstream of the MAPKKK.   
Next, we over-expressed STE4Gβ using a galactose-inducible promoter.  Since 
Gpa1 cannot sequester excess Ste4Gβ (34), the overproduced Ste4Gβ is free to activate 
effectors even in the absence of any stimulus.  TetO7-CDC4 cells containing GAL-STE4 
were grown in dextrose- or galactose-containing medium to induce protein expression.  
Overexpression of STE4 resulted in MAPK activation in the absence of pheromone.  
Once again, doxycycline treatment failed to dampen this signal (Figure 2.7 B).  Thus 
knock-down of Cdc4 attenuates signaling by pheromone but not the G protein β  subunit.  
These data indicate that SCF acts at the level of the G protein or the receptor.      
Loss of Cdc4 stabilizes Gpa1 protein levels 
Our genetic epistasis analysis indicates that Cdc4 acts early in the pathway.  We 
hypothesized further that Cdc4 must ubiquitinate a negative regulator, since knockdown
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Figure 2.7 
 
Figure 2.7  The Cdc34 E2 and SCFCdc4 regulate signaling upstream of Ste4Gβ.  
(A) TetO7-CDC4 cells were transformed with a plasmid containing either STE11-
4 (constitutively active mutant) or no insert. Cells were treated with 10 µg/mL 
doxycycline for 15 hrs and then 3 µM α factor for 30 min. Samples were analyzed by 
immunoblotting using phospho-p42/44 or G6PDH antibodies. Bar graphs represent 
quantification of the indicated bands. Results are the mean ± S.E. (n=3).  (B) TetO7-
CDC4 cells were transformed with a plasmid containing STE4 under the control of a 
galactose-inducible promoter. Cells were treated with 10 µg/mL doxycycline for 12 hrs in 
medium containing either dextrose or switched to galactose (2% w/v final concentration) 
for 3 hrs prior to α factor treatment (3 µM for 30 min). Samples were analyzed by 
immunoblotting using phospho-p42/44 or G6PDH antibodies. Bar graphs represent 
quantification of the indicated bands. Results are the mean ± S.E. (n=3). 
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of Cdc4 resulted in a decrease in signaling.  There are only two well-characterized 
negative regulators that function upstream of Ste4Gβ, Gpa1 and the RGS protein Sst2, 
and both are known to be ubiquitinated (154, 191).  To determine if Cdc4 affects Gpa1 
or Sst2 stability, we tracked their rates of degradation in a temperature-sensitive cdc4-1 
strain.  This mutant strain has been used previously in similar experiments to identify 
Cdc4 substrates (152).  The rate of Sst2 degradation was similar in both the wild-type 
and cdc4-1 cells (Figures 2.8 B and D).  In contrast, Gpa1 was considerably more stable 
in the absence of Cdc4 function.  Whereas Gpa1 in wild-type cells exhibited an 
approximate half-life of 141min, in cdc4-1 cells the half-life was extended to 344 min 
(Figures 2.8 A and C).  These data demonstrate that Cdc4 is required for proper 
turnover of Gpa1 in vivo.  Interestingly, Wang et al. showed that a  
mutant Gpa1 that cannot be ubiquitinated in vivo produces a dampened pheromone 
response (159), comparable to that seen in the SCF mutant strains (Table 2.1).  Taken 
together, these data indicate that SCFCdc4 regulates the function of Gpa1.   
We also considered whether the Cdc34/SCF complex regulates other 
components involved in G protein signaling.  To this end we measured the abundance 
and stability of proteins downstream of the receptor but upstream of the transcription 
factor (Ste4, Ste20, Ste5, Ste11, Ste7, Fus3, and Kss1).  To identify Cdc34/SCF 
substrates, including those that could be recruited by F-box proteins other than Cdc4, we 
used a temperature sensitive cdc34-2 mutant strain.  Of the proteins tested, four (Ste4, 
Ste20, Ste7, and Ste5) were significantly stabilized in the cdc34-2 mutant as compared 
with wild-type cells (Figure 2.9 A).  These data corroborate reports that the Cdc34/SCF 
pathway promotes the degradation of Ste7 and Ste5 (192, 193), and suggest that it may 
likewise act on Ste20 and Ste4.  Of these proteins at least one binds to Cdc4 (Ste5) and 
another is clearly ubiquitinated (Ste7) (192, 193).  Strikingly, despite stabilized 
expression of multiple components that propagate the signal, loss of Cdc34 or SCFCdc4 
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Figure 2.8 
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Figure 2.8  SCFCdc4 ubiquitinates Gpa1 in vitro and facilitates its turnover in vivo. 
(A) Gpa1 stability in wild-type vs. temperature-sensitive cdc4-1 mutant cells. 
Cultures were grown at 25oC, shifted to 37oC for 1 hr, and then treated with 
cycloheximide (CHX) for the indicated times. Myristoylated (bottom band) and 
unmyristoylated (top band) Gpa1 detected by immunoblotting with Gpa1 antibodies.  (B) 
Samples from panel (A) analyzed with Sst2 antibodies.  (C and D) The intensity of bands 
from (A) and (B), analyzed by densitometry. Results are the mean ± S.E. (n=3).  (E) In 
vitro ubiquitination of Gpa1. Purified Gpa1-Flag was incubated with purified SCFCdc4 
complex (Flag-Skp1/Cdc53/Myc-Rbx1/Cdc4), His6-Uba1, His6-Cdc34, and ubiquitin as 
indicated, followed by SDS-PAGE and immunoblotting. Unmodified (Gpa1) and 
ubiquitinated (Gpa1-(Ub)n) Gpa1 protein was visualized with Gpa1 antibodies. 
Membranes were also probed with Cdc4 antibodies and Cdc53 antibodies.  (F) In vitro 
ubiquitination using Lys-less ubiquitin (Ub0K).  Reactions contain either Gpa1 or Gpa1Δ128-
236, a mutant form of Gpa1 lacking the ubiquitinated subdomain.  (G) In vitro 
ubiquitination of Gpa1 using Ub0K and SCF complexes containing either Cdc4 or Met30 
as indicated. Note that Met30 appears to bind weakly to Gpa1 but does not sustain 
Gpa1 ubiquitination (Figure 2.9 B). 
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Figure 2.9 
 
Figure 2.9 The SCF does not destabilize any positive regulators of G protein 
signaling and primarily functions to ubiquitinate Gpa1. 
(A) The indicated TAP-fusion genes were integrated into wild-type and cdc34-2 ts 
strains. Cycloheximide was administered at time zero and protein levels measured by 
immunoblotting with protein A antibodies.  (B) GST-Skp1/Cdc4-HA or Met30-HA 
complexes were immobilized on Glutathione SepharoseTM resin and incubated with 
purified Gpa1-Flag, followed by washing and analysis of the bound proteins with Gpa1-
antibodies to detect co-purification of Gpa1.  (C) In vitro ubiquitination of Gpa1 
expressed in yeast and E coli, which lacks most post-translational modifications. 
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function leads to a reduction in pheromone signaling.  Furthermore, loss of CDC4 gene 
expression has no effect when the pathway is activated at the level of Ste4Gβ (Figure 
2.7).  Taken together, these findings highlight the importance of a negative regulator as 
the most functionally significant target for Cdc34/SCFCdc4-dependent degradation, and 
demonstrate that the dampened pheromone signaling in SCF-depleted cells is due 
primarily to the stabilization of Gpa1.    
Cdc34 poly-ubiquitinates purified Gpa1 in vitro in an SCFCdc4-dependent manner 
Protein turnover is often dependent upon polyubiquitination.  Gpa1 was shown 
previously to undergo ubiquitination in vivo (154).  To test the possibility that SCFCdc4 is 
directly responsible for the modification, we sought to establish whether SCFCdc4 could 
interact with Gpa1.  We affinity purified Skp1-GST/Cdc4-HA from insect cell lysates and 
added purified Gpa1-Flag.  As shown in Figure 2.9 B, Gpa1 copurified with Cdc4.  
Additionally, we tested a closely related F-box protein, Met30.  Both Met30 and Cdc4 
contain a substrate-binding domain comprised of WD repeats (99).  Gpa1 bound to 
Met30 (Figure 2.9 B), but with a lower affinity than Cdc4.  These results suggest that the 
Cdc4 component of the SCFCdc4 ubiquitin ligase complex binds Gpa1, and as a 
consequence may promote its ubiquitination by Cdc34. 
To establish whether Gpa1 is ubiquitinated by Cdc34/SCFCdc4 we sought to 
reconstitute Gpa1 ubiquitination in vitro.  We purified Gpa1-Flag from yeast (to maintain 
post-translational modifications) and purified the SCFCdc4 complex (comprised of yeast 
Flag-Skp1, Cdc53, Rbx1, and Cdc4) from insect cells.  As shown in Figure 2.8 E, Gpa1 
is polyubiquitinated in reaction mixtures composed of purified SCFCdc4, Cdc34, Uba1, 
Ubiquitin and ATP, but not in the absence of SCFCdc4 or Cdc34.  To determine if the SCF 
polyubiquitinates Gpa1 at a single site, or instead monoubiquitinates Gpa1 at multiple 
sites, we performed the in vitro ubiquitination reactions with a mutant form of ubiquitin 
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(Ub0K) that, due to the replacement of all the lysines with arginine, cannot be 
incorporated into poly-ubiquitin chains.  Under such conditions, we observed only a 
single 8kD shift, suggesting Gpa1 is modified at a single lysine residue (Figure 2.8 F).   
In order to determine if Gpa1 is ubiquitinated by the SCFCdc4 at the previously 
identified site, we conducted an in vitro ubiquitination assay using a mutant form of Gpa1 
that lacks the ubiquitinated subdomain (Gpa1Δ128-236).  As shown in Figure 2.8 F, 
Gpa1Δ128-236 is not ubiquitinated in vitro, indicating the SCFCdc4 ubiquitinates Gpa1 at the 
known site of ubiquitination.  Interestingly, Gpa1Δ128-236 is not ubiquitinated, and the 
response to pheromone is partially abrogated.  This gain-of-function phenotype is likely 
due to stabilized expression of the protein.  However we cannot rule out the possibility 
that there are other functional differences between the mutant and wild-type protein.  As 
an additional control, we conducted an in vitro reaction with the F-box protein Met30.   
We show above that Met30 was able to bind Gpa1.  However, SCFMet30 complexes were 
not able to ubiquitinate Gpa1 (Figure 2.8 G).   
Finally, the SCF complex is typically recruited to substrates in response to 
substrate phosphorylation (194).  To determine if Gpa1 ubiquitination by the SCFCdc4 is 
regulated by phosphorylation we conducted in vitro ubiquitination assays with Gpa1 from 
E. coli, which should lack all post-translational modifications.  As shown in Figure 2.9 C, 
Gpa1 expressed from E. coli is ubiquitinated poorly, indicating that Gpa1 ubiquitination 
by SCFCdc4 may be regulated by a post-translational modification.      
Notably, the Gpa1Δ128-236 mutant, which is not ubiquitinated in vivo or in vitro (159) 
(Figure 2.8 F),  exhibits a dampened pheromone response comparable to that seen 
following knock-down of SCFCdc4 expression (Table 2.1).  The ability of SCFCdc4 to 
ubiquitinate Gpa1 in vitro, and to accelerate Gpa1 turnover in vivo, reveals Gpa1 as a 
critical target of SCF regulation.  To date, only a handful of SCFCdc4 substrates have 
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been verified by direct ubiquitination using purified components.  Indeed, of the mating 
pathway components only the cell cycle regulatory protein Far1 has been characterized 
in this manner (Figure 2.10) (195).  The identification of Gpa1 as an SCFCdc4 substrate 
could explain the critical role of SCFCdc4 in pheromone signaling, and expands the 
repertoire of regulatory SCFcdc4 functions in the pheromone pathway (Figure 2.10).   
Discussion 
The yeast pheromone response system is perhaps the most thoroughly 
characterized of any signaling pathway.  The contributions of non-essential gene 
products have been exhaustively and systematically characterized over much of the past 
three decades.  Much less is known about genes that are essential to cell viability, but 
which nevertheless contribute to effective signal transduction.  Until now, only two major 
components of the pheromone signaling cascade, Gpa1 and Cdc42, were known to be 
encoded by essential genes.  To address this deficit, we conducted a systematic 
analysis of the essential yeast genome.  Our results implicate 92 essential genes in the 
regulation of G protein signaling, verify the involvement of 6 selected genes, and define 
their mode of action.  These findings suggest a level of complexity in G protein signaling 
that has not been fully appreciated.   
Protein degradation 
Among the genes required for proper pheromone responses, those involved in 
protein degradation (13 of 92 genes) were over-represented in our screen, indicating 
that they may have a particularly important role in signal regulation.  Included in this 
group are four components of the 20S proteasome, four components of the 19S 
regulatory particle (together forms the 26S proteasome complex), as well as the Cdc34 
E2 ubiquitin conjugating enzyme and the SCFCdc4 E3 ubiquitin ligase.  These data are 
consistent with the observation that many of the core components of the pheromone 
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Figure 2.10 
 
Figure 2.10  The pheromone response pathway. 
The Cdc34/SCF complex targets several known substrates in the pheromone 
response pathway. Known substrates of Cdc34/SCF are shown in dark blue. Likely 
substrates of the SCF are shown in light blue. SCFCdc4 substrates that have been verified 
using in vitro ubiquitination assays are designated with an asterisk (*). 
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pathway are ubiquitinated, including the receptor, G protein, RGS protein, and 
components of the MAP kinase cascade (154, 162, 179, 191-193, 196).  Further, there is 
indirect evidence that SCF complexes promote ubiquitination of several proteins that 
propagate the signal, including Ste5 (192), Ste7 (193), Ste4 and Ste20 (Figure 2.9 A).  
Strikingly, despite stabilized expression of these positive regulators, loss of SCFCdc4 
function results in a reduction in pheromone signaling.  A negative regulator is thus the 
most functionally significant target of the SCFCdc4 in signal transduction.  Our analysis 
indicates that Gpa1 is this critical target of the SCFCdc4.   
These findings expand the classic roles of SCF complexes in orchestrating the 
events leading to mating (Figure 2.10).  Arrest of cell division in the G1 phase is needed 
to ensure cell cycle synchrony prior to cell fusion.  Essential to G1 cell cycle arrest is 
inactivation of the cyclin-dependent kinase (CDK) Cdc28.  Several mechanisms 
contribute to the G1-specific functions of Cdc28; these include degradation of the G1 
cyclins Cln1 and Cln2, and direct inhibition of Cln/Cdc28 activity by Far1 (197), a protein 
that is upregulated in a Ste12-dependent manner during mating (198).  Additionally, 
these changes prevent proteolysis of the Sic1 S-phase CDK inhibitor, which normally 
depends on G1 CDK activity, thereby ensuring that the S-phase Cdc28 functions are not 
activated in mating cells.  Each of these processes is regulated by SCF complexes.  
Whereas SCFCdc4 promotes the ubiquitination and degradation of Far1 (179) and Sic1 
(134, 135), SCFGrr1 promotes the degradation of Cln1 and Cln2 (199, 200). 
As noted above, loss of Gpa1 leads to G1 cell cycle arrest.  Thus an additional 
role for SCFCdc4 in ubiquitination and degradation of Gpa1 is likely to contribute to cell 
cycle regulation.  Inhibition of SCFCdc4 could promote a timely recovery following 
pheromone stimulation, and also prevent pheromone signaling in non-G1 phases of the 
cell cycle when improper activation of cell mating could result in aneuploidy.  The 
observation that many of the pheromone pathway components are not expressed in 
66 
diploid cells suggests that SCF could also promote degradation of unnecessary (haploid-
specific) signaling proteins and, as such, prevent aberrant pathway activation after 
mating.   
Gpa1 as a target for proteasomal and vacuolar proteolysis 
Gpa1 is a rare example of a protein that can be either mono- or poly-
ubiquitinated (154).  Whereas polyubiquitinated Gpa1 is targeted to the proteasome, 
monoubiquitinated Gpa1 is internalized and degraded within the vacuole (159).  Left 
unresolved was whether mono- and poly-ubiquitination of Gpa1 requires two distinct sets 
of E2 and E3 enzymes.  Recently, we showed that Rsp5 monoubiquitinates Gpa1 (160).  
Here we show that the SCF complex polyubiquitinates Gpa1.  Taken together these 
findings reveal that Gpa1 mono- and poly-ubiquitination occur by distinct pathways 
and/or mechanisms.   
Although complex, there may be specific benefits to having two ubiquitinating 
pathways that can target the same protein for distinct proteolytic machineries.  One such 
benefit would be that degradation could be triggered in response to different signals 
and/or functional states of the protein.  In support of this model, we showed that the 
Rsp5 E3 ligase ubiquitinates only the fully myristoylated (fully mature) form of the G 
protein.  Myristoylated Gpa1 would localize to the plasma membrane and its degradation 
in vacuoles could therefore be linked to endocytosis.  Conversely, there may be another 
modification that directs Gpa1 to SCFCdc4.  Indeed, many E3 ubiquitin ligases including 
the SCF, are recruited to substrates in response to substrate phosphorylation (194).  
Recently, two independent phospho-proteomic screens revealed that Gpa1 is 
phosphorylated at Thr-189 and Ser-200 (201, 202), and it is noteworthy that both sites 
are located near a known Gpa1 ubiquitination site, Lys-165, established by mass 
spectrometry (158).  In this study, we show that Gpa1 purified from E. coli and lacking 
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any post-translational modifications is not ubiquitinated in vitro.  Thus phosphorylation of 
Gpa1 may serve to recruit the SCF ubiquitination machinery.  It is also possible, 
however, that phosphorylation of a Gpa1-binding partner, rather than Gpa1 itself, is 
sufficient to direct the protein to the SCFCdc4 complex.  Knowing when Gpa1 is 
phosphorylated, whether there are additional sites of phosphorylation, and the identity of 
the protein kinase(s) could further establish the role of Gpa1 ubiquitination in regulating 
the pheromone pathway. 
Interestingly, depletion of Cdc4 does not result in increased steady-state levels of 
Gpa1 (data not shown).  While any differences in Gpa1 abundance are small, even small 
differences in abundance could account for the 54% loss of signal observed in the 
TetO7-CDC4 strain.  The SCFCdc4 likely targets a small pool of Gpa1 that is functionally 
important for signaling as has been shown for other proteins (99, 203).  In this case, 
small changes in protein levels, in a specific functional context, can result in large 
changes in signaling.  We further expect that slower Gpa1 turnover in the TetO7-CDC4 
strain would increase the proportion of protein that has had time to be correctly folded, 
fully modified, properly localized, and assembled into the heterotrimeric complex.  
Unfortunately, it is not currently feasible to distinguish Gpa1 that is folded and functional 
from protein that is non-functional but nevertheless expressed in the cell. 
G protein ubiquitination may also be regulated by external stimuli.  F-box proteins 
appear to serve as receptors for the plant hormones auxin and jasmonates; in each case 
binding to these hormones enhances the interaction between SCF and its substrates 
(204-206).  Thus F-box proteins and ubiquitin ligases can function as hormone 
receptors.  By extension, F-box proteins might also serve as targets for drugs that 
enhance or diminish signaling by G proteins and G protein-coupled receptors. 
Non-proteolytic new essential regulators of G protein signaling 
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We also characterized three other essential genes required for proper G protein 
signaling.  Of particular interest are the PtdIns 4-kinases Pik1 and Stt4.  Whereas 
pheromone stimulation leads to activation of both Fus3 and Kss1, we found that 
knockdown of PIK1 or STT4 leads to a selective diminution of Fus3 activity.  These 
observations suggest a positive role for PtdIns 4-P in signal transduction, and in 
particular for Fus3.  Similarly, there is a selective loss of Fus3 activation in cells that lack 
the PtdIns 3-kinase components Vps34 and Vps15, or in cells treated with the PtdIns 3-
kinase inhibitor Wortmannin (65).  Taken together, these findings indicate a potential role 
for mono-phosphorylated phosphoinositides in Fus3 activation.  Notably, Fus3 activation 
requires the MAPK scaffolding protein Ste5, while Kss1 activation does not.  Moreover, 
Ste5 was shown to bind to PtdIns 4-P and PtdIns 4,5-P2 in vitro (207).  We hypothesize 
that PtdIns 4-P interaction is required for Ste5 activity or proper localization.  
Additionally, PtdIns 3-P and 4-P are produced in different sub-cellular locations, and 
these differences could contribute further to signaling specificity and activity.  In any 
event, these discoveries suggest an important and expanded role for phosphoinositides 
in the pheromone-response pathway.   
Conclusions 
 We have systematically characterized 870 essential genes for participation in the 
yeast G protein signaling pathway, identified up to 92 new regulators of the pathway, 
and characterized six in detail.  Our findings reveal considerable overlap among genes 
required for cell viability and signal propagation.  More significantly, our work reveals that 
there are still many new pathway components to be found.  While we focused on 
components for which there was a specific and rigorously-testable hypothesis, there are 
still dozens of others that will be pursued in the future.  Based on these results, we 
regard the essential-genome as an under-utilized resource for the identification of new 
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signal transduction factors.  Further efforts to screen the essential genes in yeast and 
other model systems will undoubtedly lead to a more complete understanding of signal 
transduction networks.  Given the conservation of G protein function across species, 
newly described functions in yeast are likely to extend as well to humans.  Due to the 
established importance of G proteins in physiology and pharmacology, our findings may 
also reveal future opportunities for drug discovery.   
Experimental Procedures 
Strains and plasmids - Standard procedures for the growth, maintenance, and 
transformation of yeast and bacteria and for the manipulation of DNA were used 
throughout.  Yeast Saccharomyces cerevisiae strains used in this study were BY4741 
(MATa leu2Δ met15Δ his3-1 ura3Δ), MTY235 (MATa ade2-1 his3-11,15 leu2-3,112 trp1-
1 ura3-1 can1-100), MTY670 (MTY235 cdc34-2), and MTY668 (MTY235 cdc4-1) 
(provided by Mike Tyers, Samuel Lunenfield Research Institute) (152), BY4741-derived 
strains containing a C-terminal tandem affinity purification (TAP)-tag (Yeast TAP-Fusion 
Library, Open Biosystems), and the BY4741-derived strain R1158 (MATa URA3::CMV-
tTA leu2Δ met15Δ his3-1 ura3Δ) (208).  The tetracycline-repressible strains were 
purchased as the yeast Tet-promoter Hughes Collection (yTHC, Open Biosystems) (28).   
Yeast shuttle plasmids used were pRS315 (CEN, ampR, LEU2), and pRS316 
(CEN, ampR, URA3).  Expression plasmids described previously were pRS423-FUS1-
lacZ (209), pRS316-ADH1, pRS316-ADH1-GPA1 (78), pFAGa-mRFP1-KanMX6 (210), 
pUG35 (provided by Johannes Hegemann, Heinrich-Heine-Universität), YCp50-STE11-4 
(from George Sprague, University of Oregon) (190), and pRS315-GAL-STE4 (175).  
Plasmid pRS316-ADH-GPA1-Flag was constructed by PCR amplification of a 384 bp 
fragment of GPA1 from pRS316-ADH-GPA1 using primers 1 and 2 (see Appendix I).  
Plasmid pRS316-ADH-GPA1Δ128-236-Flag was constructed by QuikChange (Stratagene) 
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using primers 3 and 4 to remove the 324 bp fragment corresponding to amino acids 128-
236.  Plasmid pRS315-STE11 was constructed by PCR amplification of STE11 from 
BY4741 genomic DNA, followed by SacI and XmaI digestion and ligation into the 
corresponding sites of pRS315.  Plasmid pRS315-STE11-4 was constructed by 
engineering the single point mutation Thr-596-Ile (190) into pRS315-STE11 using 
QuikChange and primer 5 and its complement.  Rescue plasmids for CDC4, CDC34, 
and STT4 were constructed by PCR amplification of each gene from BY4741 genomic 
DNA, followed by SacI and XmaI digestion and ligation into the corresponding sites of 
pRS315.  Rescue plasmids for PIK1 and MPS1 were made in a similar manner except 
that SacII was used in place of SacI. 
The pRS316-ADH1-RFP/FUS1-GFP (AR/FG) dual reporter was constructed 
using the steps outlined below.  The plasmid pRS316-ADH1-GFP was constructed by 
PCR amplification of GFP from the plasmid pUG35 using primers 6 and 7 including SacI 
sites, followed by SacI digestion and insertion into the corresponding site in pRS316-
ADH1.  The ADH1 terminator sequence (ADH1t) (from the stop codon to 600bp 
downstream) was PCR amplified from genomic DNA with primers 8 and 9 including 
XmaI and SalI sites.  The resulting PCR product was digested with XmaI and SalI and 
inserted into the corresponding sites in pRS316-ADH1-GFP, resulting in pRS316-
ADH1p-ADH1t-GFP.  RFP was PCR amplified from pFA6a-mRFP1-KanMX6 using 
primers 10 and 11 with XmaI sites.  This fragment was ligated into the corresponding 
XmaI sites of pRS316-ADH1p-ADH1t-GFP, resulting in the plasmid pRS316-ADH1p-RFP-
ADH1t-GFP.  The FUS1 promoter (FUS1p) (600bp upstream of the start codon of FUS1) 
was PCR amplified from genomic DNA using primers 12 and 13 containing SalI sites.  
The resulting fragment was digested with SalI and inserted into the corresponding sites 
of pRS316-ADH1p-RFP-ADH1t-GFP resulting in the plasmid pRS316-ADH1p-RFP-
ADH1t-FUS1-GFP (designated pRS316-AR/FG).  pRS315-AR/FG was constructed by 
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digestion of pRS316-AR/FG with PvuI and ligation into the corresponding sites in 
pRS315. 
Screen of essential genes - 852 TetO7 promoter strains (Open Biosystems, 
yTHC) were transformed with pRS423 FUS1-lacZ, and β-galactosidase activity was 
measured in a 96-well plate format as described previously (177).  Prior to pheromone 
stimulation, cells were grown for ~15 hrs in either untreated medium or medium 
containing 10 ng/mL, or 100 ng/mL doxycycline hyclate (Sigma-Aldrich).  β-
galactosidase activity was measured in triplicate for each condition.  Strains were 
considered for further analysis if doxycycline treatment resulted in a >50% increase or 
decrease in maximal response, at least a two standard deviation shift in the EC50, or at 
least a four-fold increase in the basal activity as determined by non-linear regression 
analysis (Graphpad Prism).  Twenty-six candidate strains were re-tested individually 
using twelve concentrations of α factor pheromone and a higher dose of doxycycline (10 
µg/mL).  Eleven confirmed strains were transformed with the pRS316-AR/FG dual 
reporter and tested for GFP and RFP expression by immunoblotting.  While all eleven 
strains exhibited changes in GFP expression, three TetO7-strains representing the 
essential genes RIO2, KIC1, and SSY1 also exhibited detectable changes in RFP 
expression and were not considered further.  The remaining eight TetO7-strains 
representing the essential genes MPS1, STT4, PIK1, CDC4, CDC53, CDC34, PMA1, 
and SLN1 showed no change in RFP expression.  Of the remaining eight strains, six 
were selected for transformation with a single-copy plasmid containing the 
corresponding wild-type gene, and these were re-tested for restoration of normal β-
galactosidase activity (Table 2.1).   
Bioinformatics - Physical and genetic interactions among the genes identified in 
the screen were analyzed using Osprey Network Visualization System (181) which 
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incorporates published data from the Biological General Repository for Interaction 
Datasets (BioGRID) (182).  Functional categories were assigned based on Gene 
Ontology annotations using Functional Clustering in Osprey.  Genes involved in multiple 
GO processes were assigned a single GO term based on Osprey’s hierarchical GO 
process order.  Hierarchical clustering of TetO7-Strain phenotypes was conducted with 
the open source software Cluster 3.0 (211) using uncentered correlation and centroid 
linkage.  The generated clustering data was visualized with the open source software 
Java TreeView (v1.1.3) (212). 
Cell-extract preparation and immuno-blot analysis - The yeast TetO7 strains 
were grown in selective medium to A600nm~0.8 and re-inoculated at 1:80 into medium 
containing doxycycline at a final concentration of 10µg/ml and grown to A600nm~0.8.  Cell 
cultures were then divided in half, and either treated with 3 µM α factor pheromone or 
left untreated at 30oC for 30 min.  Protein extracts were produced by glass bead lysis in 
trichloroacetic acid (TCA) as previously described (19).  Protein extracts were resolved 
by 12% SDS-PAGE and immunoblotting with Phospho-p44/42 MAPK antibodies (9101L, 
Cell Signaling Technology) at 1:500, Fus3 antibodies (sc-6773, Santa Cruz 
Biotechnology, inc.) at 1:500, GFP antibodies (632375, BD Biosciences) at 1:500, 
dSRed antibodies (632496, Clontech) at 1:1000, and G6PDH antibodies (A9521, Sigma-
Aldrich) at 1:100,000.  Immunoreactive species were visualized by chemiluminescent 
detection (PerkinElmer Life Sciences LAS) of horseradish peroxidase-conjugated 
antibodies (170-5047 and 170-5046, Bio-Rad).  Protein concentration was determined 
by Dc protein assay (Bio-Rad Laboratories).  Where indicated, TetO7 cells were 
transformed with pRS315-GAL-STE4, pRS315-STE11-4, pRS315-ADH-RFP/FUS1-
GFP, or empty vector, and grown in selective medium containing 2% (w/v) dextrose or 
galactose to induce STE4 expression.   
Protein turnover measurements - Cells were grown in 100 mL of selective 
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medium at room temperature to A600nm ~0.6, and then shifted to 37oC for 1hr.  Cells were 
then treated with cycloheximide (final concentrations, 10 µg/mL in 0.1% ethanol) for up 
to 3 hrs.  Growth was stopped by the addition of TCA (5% final concentration) and 
samples were normalized to the same A600nm.  Cell pellets were washed and brought up 
directly in boiling SDS-PAGE sample buffer (62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 
2% SDS, 1% 2-mercaptoethanol, 0.0005% bromophenol blue) and lysed using glass 
beads as previously described (213).  Protein extracts were resolved by 10% SDS-
PAGE and immunoblotting with Gpa1 antibodies at 1:1000 (76) and Sst2 antibodies at 
1:2000 (214).   
TAP-fusion protein turnover screen - TAP-fusion genes were PCR amplified 
and integrated into MTY235 and cdc34-2 cells.  Cells were grown at room temperature 
to A600nm ~0.25, shifted to 37oC for 3h rs treated with 3 µM α factor for 1 hr, and treated 
with cycloheximide for up to 90 min.  Protein extracts were resolved by 7.5% SDS-PAGE 
and immunoblotting with protein A (P3775, Sigma-Aldrich) antibodies at 1:50,000.  
Experiments were performed in triplicate, and bands were quantified by densitometry. 
Preparation and purification of recombinant proteins - BY4741 yeast cells 
were transformed with pRS316-ADH1-GPA1-Flag and pRS316-ADH1-GPA1Δ128-236-Flag 
and grown to early log phase (A600nm ~1.0) before harvesting by centrifugation.  The cell 
pellet was frozen in liquid nitrogen and lysed by grinding cells blast-frozen in a 1:0.7 ratio 
of lysis buffer (50 mM Tris-HCl, pH 7.5, 400 mM KCl, 0.1% Triton, 0.2 mM dithiothreitol) 
supplemented with 20 µM GDP, 10 mM NaF, 10 mM β-glycerol phosphate, 1 mM 
sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride and 1 proteinase inhibitor 
tablet per 50mL (11873580001, Roche Applied Science).  The cell lysate was thawed on 
ice, and centrifuged at 15,000xg for 30 min at 4oC.  The supernatant was transferred and 
incubated with EZview anti-Flag M2 beads (Sigma-Aldrich) for 2 hrs rotating at 4oC.  
74 
Beads were harvested by centrifugation and washed 3 times with 100x bead-bed volume 
of ubiquitination buffer (50 mM Tris-HCl, pH 7.5, 50 mM KCl, 0.2 mM dithiothreitol, 2 mM 
MgCl2, 20 µM GDP) supplemented with 5% glycerol, followed by elution with 2x bead-
bed volume of the supplemented ubiquitination buffer containing 0.25 mg/mL 3XFlag 
peptide (Sigma-Aldrich).  Protein aliquots were frozen and stored at -80oC.   
Yeast HisCdc4 E2 was purified from E. coli, yeast HisUba1 E1 was purified from 
yeast, and yeast SCF E3 Complexes were purified from insect cells infected with the 
baculoviruses expressing yeast Flag-Skp1, Cdc53, Myc-Rbx1, and HA-Cdc4 or HA-
Met30 for 40 hrs as described previously (135).  Cells were disrupted in NETN buffer (50 
mM Tris-HCl, pH7.5, 150 mM KCl, 0.5% Nonidet P-40, 0.2 mM dithiothreitol, 10 mM 
NaF, 10 mM β-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride) supplemented 
with proteinase inhibitor tablets and cleared by centrifugation at 15,000xg for 30 min at 
4oC.  Typically 3 mL of NETN buffer was used per 0.5 x 108 cells.  For 
immunopurification 300 µL of cell lysate was incubated with 10 µL EZview anti-Flag M2 
beads with rotating for 1 hr at 4oC.  Beads were washed 3 times with 500 µL of NETN 
buffer for 5 min each with rocking and 3x quick washes with 500 µL of ubiquitination 
buffer.  Bound protein was eluted from the beads with 2x 10 µL of ubiquitination buffer 
supplemented 0.25 mg/mL 3XFlag peptide for 10 min each.  Eluted protein was added 
directly to ubiquitination reactions. 
6xHIS-Gpa1 expression plasmid was described previously (215) and transformed 
into BL21 (DE3) E. coli.  Cells were grown from a single colony overnight at 37oC in 
Luria Broth (LB) supplemented with 100 µg/mL carbenicillin and then diluted 1:100 into 
fresh media.  Once cells grew to A600nm ~0.7, 6xHIS-Gpa1 expression was induced by 
addition of 0.2 mM isopropyl β-D-1-thiogalactopyranoside and incubation at room 
temperature for 5 hrs with shaking.  Cells were harvested by centrifugation, resuspended 
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in Buffer A (20 mM Tris pH 8.0, 200 mM NaCl, 5% glycerol, 20 µM GDP, 2 mM MgCl2, 1 
mM DTT) supplemented with protease inhibitor tablets (Roche), and homogenized with 
an Emulsiflex-C5 Homogenizer (Avestin).  Lysates were clarified by centrifugation at 
12,000xg for 30 min, and the resulting supernatent was mixed with Buffer A-equilibrated 
Ni-SepharoseTM6 Fast Flow resin (GE Healthcare) for 2 hrs rotating at 4oC.  Resin was 
collected by centrifugation at 500xg for 5 min and washed 3 times with Buffer A followed 
by elution with Buffer A supplemented with 250 mM imidazole.  The elution was mixed 
with His-tagged tobacco etch virus protease (to remove the N-terminal 6xHIS from 
Gpa1) and dializyed in 1 L of Buffer B (20 mM Tris, pH 8.0, 100 mM NaCl, 5% glycerol, 
20 µM GDP, 2 mM MgCl2, 1 mM DTT) overnight.  Sample was incubated with Ni-
Sepharose resin for 1hr to remove tobacco etch virus protease and cleavage products.  
Flow-through from the Ni-Sepharose was concentrated using Vivaspin concentrators 
(Vivascience AG). 
Co-immunoprecipitation assay - Insect cell lysates containing GST-Skp1 and 
either Cdc4-HA or Met30-HA where mixed with Glutathione SepharoseTM 4 Fast Flow 
resin (GE Healthcare) for 1hr rotating at 4oC.  The beads were then washed 3x with 50x 
bead-bed volume of binding buffer (50 mM Tris-HCl, pH 7.5, 15 0mM KCl, 0.5% NP-40, 
0.2 mM dithiothreitol, 2 mM MgCl2, 20 µM GDP, 10 mM NaF, 10 mM β-glycerol 
phosphate, 1 mM sodium orthovanadate, and proteinase inhibitor tablets).  Gpa1-Flag 
purified from yeast was added to the beads and incubated for 2 hrs at 4oC with rotating.  
The beads were washed 3x with 50x bead-bed volume of binding buffer for 5min each 
with rocking and 3x quick washes with 50x bead-volume of binding buffer.  Bound 
protein was then eluted in 2x bead-bed volume of binding buffer supplemented with 20 
mM glutathione.  Protein samples were resolved by 10% SDS-Page and immunoblotting 
with Gpa1 antibodies at 1:1000 and HA antibodies (3F10, Roche Applied Sciences) at 
1:2000. 
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In vitro ubiquitination assay - Ubiquitination reactions were prepared with 
FlagSCF complexes containing Flag-Skp1/Cdc53/Myc-Rbx1/Cdc4 or Met30 purified from 
insect cells as described in Supplemental Methods, and in (135).  9 µL of purified and 
eluted SCF complex (~2 pmol) was combined with 13.5 pmol HisCdc34, 1.0 pmol 
HisUba1, 120 pmol Ub or 0K Ub (Boston Biochem), 1.5 pmol Gpa1-Flag and 
supplemented with 1mM ATP, 5mM MgCl2, and 20µM GDP in a volume of 15 µL.  
Reactions were allowed to proceed at 30oC and stopped after 90min with the addition of 
boiling SDS-PAGE sample buffer, followed by SDS-PAGE and immunoblotting with 
Gpa1 antibodies.  Membranes were stripped and re-probed with Cdc4 antibodies at 
1:1000 and Cdc53 antibodies at 1:1000 (provided by Mark Goebl, University of Indiana 
Medical School).   
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Summary 
 Multiple mitogen-activated protein (MAP) kinase pathways share components yet 
initiate distinct biological processes.  Signaling fidelity can be maintained by scaffold 
proteins and restriction of signaling complexes to discreet subcellular locations.  For 
example, the yeast MAP kinase scaffold Ste5 binds to phospholipids produced at the 
plasma membrane and promotes selective MAP kinase activation.  Here we show that 
Pik1, a phosphatidylinositol (PtdIns) 4-kinase that localizes primarily to the Golgi, also 
regulates MAP kinase specificity, but does so independently of Ste5.  Pik1 is required for 
full activation of the MAP kinases Fus3 and Hog1 and represses activation of Kss1.  
Further, we show by genetic epistasis analysis that Pik1 likely regulates Ste11 and 
Ste50, components shared by all three MAP kinase pathways.  These findings reveal a 
new regulator of signaling specificity functioning at endomembranes rather than at the 
plasma membrane. 
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Introduction 
Cells growing in complex environments are exposed to multiple chemical and 
physical stimuli.  Many external stimuli activate mitogen-activated protein (MAP) kinase 
pathways to elicit intracellular biological processes.  In some cases, a single stimulus will 
activate multiple MAP kinases, yet signaling specificity is maintained (216).  How cells 
regulate the activation of different MAP kinase pathways to invoke the appropriate 
biological response is not well understood.   
The yeast Saccharomyces cerevisiae provides a versatile model for 
understanding the coordinated regulation of multiple MAP kinases.  In yeast, three well-
characterized MAP kinase pathways respond to different external stimuli to initiate 
distinct, and sometimes mutually exclusive, biological processes (Figure 3.1 A) (217).  
First, mating pheromones activate a pathway that induces cell cycle arrest, polarized cell 
expansion, and the fusion of haploid a- and α-type cells to form an a/α diploid.  This 
process is mediated by a heterotrimeric G protein and a protein kinase cascade 
comprised of Ste20, Ste11, Ste7, and the MAP kinase Fus3 (178).  Second, nutrient 
deprivation results in the activation of the same kinase components, with the exception 
of the MAP kinase, Kss1 (218, 219), and induces filamentous growth as well as 
increased adherence and invasion into the substratum (220).  Third, osmotic stress 
activates the MAP kinase Hog1 in the high osmolarity glycerol (HOG) response pathway 
(221), and induces glycerol production to counterbalance osmotic pressure and enable 
cell survival (222, 223).   
Despite profound differences in stimulus and response, different MAP kinase 
pathways will often share signaling components.  For example, the MAP kinase kinase 
kinase Ste11 and its adapter protein Ste50 are shared by the mating, filamentous 
growth, and HOG pathways (224-226).  Ste7 is shared by the mating and filamentous 
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Figure 3.1  Pik1 is required for proper pheromone signaling.  
(A) Three yeast MAP kinase pathways respond to different stimuli and regulate 
distinct biological processes, yet all three pathways share signaling components. The 
MAP kinase kinase kinase Ste11 and the adapter Ste50 regulate all three pathways.  (B) 
TetO7-PIK1 cells were transformed with the FUS1-lacZ transcription reporter and 
pRS315-PIK1 (pPIK1) or pRS315 (Vector) and treated with a factor pheromone at the 
indicated concentration for 90 min. β-galactosidase activity was measured 
spectrofluorometrically. Inset is activity in cells not stimulated with a factor.  (C) TetO7-
STT4 cells were transformed with the FUS1-lacZ reporter and pRS315-STT4 (pSTT4) or 
empty vector (Vector) and treated with a factor pheromone. Results are the mean ± S.E. 
for three individual experiments each performed in triplicate.  
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pathways (217).  Yet remarkably little pathway cross-talk is observed.  In the pheromone 
response pathway, MAP kinase specificity is maintained by the scaffold protein Ste5, 
which binds Ste11, Ste7, and Fus3 (227).  Upon pheromone stimulation, Ste5 
translocates to the plasma membrane by binding to G protein βγ subunits (228) and 
facilitates signal propagation through Fus3, but not Kss1 or Hog1 (229).  In the HOG 
pathway, specificity is maintained by another scaffold protein Pbs2, which also functions 
as the kinase that activates Hog1.  However, despite the existence of these scaffolds, 
Kss1 is still partially activated in response to pheromone (230, 231) and osmotic stress 
(232).  Therefore, scaffolds that associate with Fus3 or Hog1 are not sufficient to prevent 
activation of Kss1.  Additional mechanisms are likely to be required to maintain proper 
balance between Fus3, Hog1, and Kss1 activation.   
Previous reports demonstrated a role for phospholipids in maintaining signaling 
fidelity.  For example, deletion of the PtdIns 3-kinase Vps34, alters Fus3 activation but 
not Kss1 (65), indicating that phosphorylated phosphoinositides may play an important 
role in maintaining MAP kinase specificity.  Ste5 is likewise required for Fus3 activation; 
Ste5 binds PtdIns 4-P and PtdIns 4,5-P2 in vitro (207, 233) and Ste5 translocation to the 
plasma membrane in vivo requires the PtdIns 4-kinase Stt4 and the PtdIns 4-P 5-kinase 
Mss4 (75, 233).  While both Stt4 and Mss4 localize primarily to the plasma membrane 
(188, 234), Vps34 localizes to endosomes (235, 236).  Together these findings show 
that phospholipids play an important role in maintaining MAP kinase specificity, and 
these phospholipids do not necessarily function at the plasma membrane. 
In a recent screen of essential genes we identified regulators of pheromone 
signaling including Stt4, as well as a second PtdIns 4-kinase Pik1 (161).  As noted 
above Stt4 promotes the activation of Fus3.  Here we show that Pik1 regulates the 
activity of three different MAP kinases in yeast.  Whereas Pik1 enhances Fus3 and Hog1 
activation, it inhibits Kss1 activation.  We demonstrate further that Pik1 regulates MAP 
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kinase signaling through a mechanism distinct from that of Stt4.  Whereas Stt4 acts by 
promoting Ste5 translocation to the plasma membrane (75), Pik1 exerts its effects 
through Ste11 and the adapter protein Ste50.  These findings reveal a novel role for 
PtdIns 4-P at endomembranes in maintaining specificity across multiple MAP kinase 
pathways.   
Results 
Pik1 is required for proper pheromone signaling  
In a recent screen to identify essential genes required for proper pheromone 
signaling, we identified two PtdIns 4-kinases, Stt4 and Pik1.  While Stt4 and Pik1 have 
the same enzymatic activity, they are both essential, suggesting they have non-
redundant functions in vivo (237).  Furthermore, Stt4 and Pik1 localize to different parts 
of the cell: Stt4 at the plasma membrane (188), and Pik1 at the Golgi and nucleus (189).  
Given that depleting the cell of either STT4 or PIK1 diminishs pheromone signaling 
(161), we reasoned they might likewise have non-redundant functions in the pheromone 
response pathway.  Stt4 has a known role promoting Ste5 translocation to the plasma 
membrane (75).  Here we investigate the signaling properties of Pik1. 
Previous research on Pik1 and Stt4 was conducted using temperature-sensitive 
(ts) alleles.  The use of ts alleles requires growth at suboptimal temperatures and 
introduces destabilizing mutations that could alter enzyme function or protein-protein 
interactions.  Growth at high temperatures can impair MAP kinase activity independent 
of any gene mutations.  For example Garrenton et al. reported a ~50% reduction in Fus3 
activation in wild-type cells grown at 37oC vs. 26oC, (see Figure 5 in (75)).  Thus the use 
of higher growth temperatures could obscure small differences resulting from partial loss 
of function ts alleles. 
To best determine the contribution of Pik1 in pheromone signaling, and to verify a 
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role for Stt4, we used strains where the native promoter was replaced with a 
doxycycline-repressible (TetO7) promoter.  Cells were grown in the presence or absence 
of doxycycline to repress gene expression.  Pathway activation was measured using a 
highly specific pheromone-inducible promoter (from FUS1) fused to the β-galactosidase 
gene.  As shown in Figure 3.1, knockdown expression of TetO7-PIK1 or TetO7-STT4 
results in dampened transcriptional output upon pheromone stimulation.  Furthermore, 
knockdown of PIK1 results in constitutive activation in the absence of pheromone (161).  
Thus, knockdown of PIK1 paradoxically yields both a dampened maximum response 
and increased basal activity.  To confirm the integrity of these strains, we expressed 
single-copy plasmids containing the wild-type gene in the corresponding TetO7 strain.  
For both PIK1 (Figure 3.1 B) and STT4 (Figure 3.1 C), introduction of the absent gene 
restored normal pheromone responses.    
To determine if depletion of PIK1 results in a subsequent loss of intracellular 
PtdIns 4-P, we visualized PtdIns 4-P in vivo using three well-characterized GFP-tagged 
biosensors.  First, the pleckstrin homology (PH) domain from phospholipase Cδ (PHPLCδ-
GFP) binds specifically to PtdIns 4,5-P2 at the plasma membrane and has been used to 
monitor plasma membrane pools of both PtdIns 4-P and PtdIns 4,5-P2 (238).  Second, 
the PH domain from FAPP1 (PHFAPP1-GFP) binds specifically to PtdIns 4-P at the Golgi 
(238).  Third, the C2 (conserved region-2) domain from bovine lactadherin (C2lact-GFP) 
binds phosphatidylserine (PS), an abundant component of all membranes (239) and 
serves as a reference control.  Knockdown of PIK1 resulted in a partial loss of Golgi 
staining of PHFAPP1-GFP but no change in localization of PHPLCδ-GFP or C2lact-GFP 
(Figure 3.2 A).  In contrast, knockdown of STT4 resulted in a partial loss of plasma 
membrane staining of PHPLCδ-GFP but no change in localization of PHFAPP1-GFP or C2lact-
GFP (Figure 3.2 B) (188).  Thus, partial knockdown of either PIK1 or STT4 is sufficient to  
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Figure 3.2  Knockdown of PIK1 or STT4 results in loss of PtdIns 4-P in vivo.  
GFP fluorescence of cells expressing a single copy plasmid pRS316 containing 
GFP fusion proteins of PHPLCδ, PHFAPP1, or C2Lact and treated with 10 µg/mL doxycycline 
(Dox) for 15 hr, as indicated.  (A) TetO7-PIK1.  (B) TetO7-STT4.  
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observe a dampened pheromone response, underscoring the importance of PtdIns 4-P 
in maintaining proper pheromone signaling. 
Loss of Pik1 induces elongated growth  
Cells exposed to pheromone undergo cell cycle arrest and form mating 
projections in preparation for mating (“shmoo” morphology).  At low doses of 
pheromone, cells continue to divide in a bipolar fashion and elongate along pheromone 
gradients in the direction of a potential mating partner (chemotropic growth) (240-243).  
When elongated cells encounter a sufficiently high level of pheromone, they undergo cell 
cycle arrest and form shmoos.  Since knockdown of PIK1 results in constitutive induction 
of pheromone-responsive genes (see Figure 3.1 B and inset), we considered whether 
these cells also exhibit an altered morphology.  DIC microscopy revealed that PIK1 
knockdown results in large and elongated cells, even in the absence of pheromone 
(Figure 3.3 A).  The observed cellular elongation was most similar to that of cells 
exposed to low doses of pheromone (240-243) and is consistent with our observation 
that PIK1 knockdown results in a small, but significant, increase in basal activation of the 
pheromone pathway.  Conversely, knockdown of STT4 has no effect on cell morphology, 
suggesting further that Pik1 and Stt4 regulate signaling in fundamentally different ways.   
Pik1 regulates pheromone signaling independently of Ste5  
Prior to pheromone stimulation, the MAP kinase scaffold Ste5 is localized 
diffusely in the nucleus and cytoplasm.  After pheromone stimulation, Ste5 translocates 
to the plasma membrane.  In an stt4ts strain, however, Ste5 is no longer localized to the 
plasma membrane, most likely due to diminished synthesis of PtdIns 4-P or PtdIns 4,5-
P2 (75, 228, 233).  Accordingly, Stt4 (like Ste5) is required for full activation of Fus3.  
Pik1 also generates PtdIns 4-P and is required for Fus3 activity, yet Pik1 is absent from 
the plasma membrane.  Thus we investigated whether Pik1 affects Ste5 localization in 
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Figure 3.3  Pik1 does not alter Ste5 localization.  
(A) DIC image of TetO7-PIK1 and TetO7-STT4 cells treated with 10 µg/mL 
doxycycline for 90 min where indicated (+ Dox).  (B) GFP fluorescence of TetO7-PIK1 
cells expressing pRS316-Ste5-(GFP)x3. Cells were treated with doxycycline for 90 min 
and 3 µM α factor pheromone for 90 min. Arrow heads indicate Ste5-GFP localized to 
shmoo tips.  Arrows indicate absence of Ste5-GFP at shmoo tips.  (C) TetO7-STT4 cells 
treated as in (B).  
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some other way.  To this end we expressed STE5-(GFP)x3 in a TetO7-PIK1 strain and 
treated cells with and without α factor pheromone.  Consistent with previous data from ts 
strains, knock down of PIK1 had no effect on Ste5-GFP localization (Figure 3.3 B) while 
knock down of STT4 resulted in a marked loss of Ste5-GFP from the shmoo tip (Figure 
3.3 C).  These results indicate that Ste5 translocation to the plasma membrane requires 
Stt4 but is unaffected by Pik1.   
In addition to binding phospholipids, Ste5 binds several signaling components 
including Gβγ (228) and all three kinases in the MAP kinase cascade: Ste11, Ste7, and 
Fus3 (176, 187).  While available evidence indicates that Stt4 helps to recruit this 
scaffolded complex to the plasma membrane, the differences between Stt4 and Pik1 
suggest that Pik1 might activate the complex without contributing to Ste5-membrane 
association.  To test this model, we tethered Ste5 to the plasma membrane using a C-
terminal transmembrane (CTM) fusion protein and expressed it under the control of a 
galactose-inducible promoter.  Ste5-CTM results in constitutive association of the MAP 
kinase cascade with upstream activators, and therefore results in constitutive activation 
of Fus3.  Ste5-CTM is localized only at the plasma membrane and therefore should not 
interact with Pik1 or PtdIns 4-P at the Golgi or nucleus (228).  We then monitored Fus3 
activation, using an antibody that recognizes the dually phosphorylated and fully 
activated form of the kinase.  As shown in Figure 3.4, Ste5-CTM strongly activates Fus3 
(228).  As expected, Fus3 activity was largely unaffected by the loss of STT4 (Figure 3.4 
A).  In contrast, this response was substantially diminished by the loss of PIK1 (Figure 
3.4 B).  Thus Stt4 and Pik1 regulate MAP kinase signaling by distinct mechanisms.  
Whereas expression of Ste5-CTM bypasses a need for PtdIns 4-P at the plasma 
membrane, these cells remain sensitive to changes in PtdIns 4-P by Pik1 within the cell. 
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Figure 3.4 
 
Figure 3.4  Pik1 regulates pheromone signaling independently of Ste5.  
(A) TetO7-STT4 cells were transformed with pRS313-GAL1-STE5-CTM and 
grown in selective medium containing dextrose or galactose to induce STE5-CTM 
expression. Cells were treated with 10 µg/mL doxycycline for 90 min and 3 µM α factor 
pheromone for 30 min, as indicated. Cell lysates were resolved by 12.5% SDS-PAGE 
and immunoblotting with phospho-p44/42 antibodies (P-Kss1, P-Fus3) and G6PDH 
antibodies as a loading control. Phosphorylated and activated Fus3 (P-Fus3) was 
quantified by scanning densitometry and analyzed with ImageJ software. Results were 
normalized to P-Fus3 levels of untreated samples. Bar graphs represent quantification of 
the indicated bands. Results are the mean ± S.E. (n=3).  (B)TetO7-PIK1 cells treated as 
in (A). Results are the mean ± S.E. (n=3). 
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Pik1 is required for full Fus3 activation and inhibits Kss1 activation  
Although necessary for Fus3 signaling, Ste5 actually slows the rate of Fus3 
activation (244).  A second MAP kinase Kss1 is also activated by pheromone, but is not 
scaffolded and is activated comparatively quickly (240).  To determine if STT4 or PIK1 
affects the kinetics of activation, we monitored Fus3 and Kss1 at multiple time points 
following pheromone treatment.  While knockdown in either case reduced the magnitude 
of Fus3 phosphorylation, the dynamics of activation were largely unchanged: Fus3 
activation remained slow while Kss1 activation remained fast (Figure 3.5 A and 3.5 B).  
There were however notable differences in the behavior of Kss1.  In contrast to STT4, 
loss of PIK1 resulted in marked elevation of Kss1 activity, particularly in the absence of 
pheromone stimulation (Figure 3.5 A).  The 22-51% increase in Kss1 activation is 
particularly striking when compared to the 28-61% reduction in Fus3 activation.  
Considering that Kss1 induces chemotropic growth at low doses of pheromone, these 
data are consistent with the observed elongated growth upon PIK1 knockdown (Figure 
3.3 A).  Treatment of cells harboring the TetO7 promoter attached to a non-expressible 
genetic element (TetO7-WT) with doxycycline had no effect on activation of Fus3 or 
Kss1, indicating that doxycycline alone has no effect on pathway activation (Figure 3.6 
A).   
As an additional control we monitored MAP kinase activity in cells lacking Vps34, 
a PtdIns 3-kinase required for full activation of Fus3 (65) (Figure 3.5 C).  Again the 
dynamics of activation were largely unaltered (Figure 3.5 C), even as overall Fus3 
activity was diminished by 29-66%.  The reduction we observed here is comparable to 
that reported by Slessareva et al. (65) but somewhat greater than the ~20% difference 
reported by Garrenton et al. (75).  These data reveal that Pik1 differentially regulates 
MAP kinase activation and is required to maintain MAP kinase specificity.  Whereas Pik1  
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Figure 3.5  Pik1 is required for full Fus3 activation and represses basal Kss1 
activation. 
(A) TetO7-PIK1 cells were treated with 10 µg/mL doxycycline for 90 min and 3 µM 
α factor pheromone for the times indicated. Cell lysates were resolved by 12.5% SDS-
PAGE and immunoblotting with phospho-p44/42 antibodies (P-Fus3 and P-Kss1), Fus3 
antibodies, or G6PDH antibodies as a loading control. Note that pheromone stimulation 
induces FUS3 but not KSS1 expression. Bands were quantified by scanning 
densitometry and analyzed with ImageJ software. Results are the mean ± S.E. (n=3).  
(B) TetO7-STT4 cells treated as in (A).  (C) BY4741 (WT) and isogenic vps34Δ cells 
treated as in (A) except that no doxycycline was added to the cultures. 
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Figure 3.6 
 
Figure 3.6  Doxycycline treatment does not affect Fus3, Kss1, or Hog1 activation.  
(A) Cells harboring a doxycycline-repressible promoter attached to a non-
expressible genetic element (TetO7-WT) were treated with 10 µg/ml doxycycline (Dox) 
for 15 hr and 3 µM α factor pheromone for the times indicated. Cell lysates were 
resolved by 12.5% SDS-PAGE and immunoblotting with phospho-p44/42 antibodies, 
which recognize the dually phosphorylated and activated form of Fus3 (P-Fus3) and 
Kss1 (P-Kss1), Fus3 antibodies, or glucose-6-phosphate dehydrogenase (G6PDH) 
antibodies as a loading control.  Note that pheromone stimulation induces FUS3 but not 
KSS1 expression. Bands were quantified by scanning densitometry and analyzed with 
ImageJ software. Results are the mean ± S.E. (n=3).  (B), as in (A), but cells were 
treated plus and minus 0.5 M KCl for the times indicated instead of pheromone. 
Immunoblots were analyzed with phospho-p38 (P-Hog1) antibodies, phospho-p44/42 (P-
Kss1) antibodies, Hog1 antibodies, or G6PDH antibodies as a loading control. 
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is required for stimulus-dependent activation of Fus3, it is also required to limit the 
activation of Kss1. 
Pik1 functions at the level of Ste11  
Given that Pik1 activates Fus3 while inhibiting Kss1, we hypothesized that Pik1 
must regulate a pathway component upstream of both kinases.  In order to better define 
which component is targeted by Pik1, we took a genetic epistasis approach.  Using 
constitutively active mutants we stimulated the pathway at multiple points, bypassing the 
need for pheromone and the pheromone receptor.  First we overexpressed the G protein 
βγ subunits (STE4Gβ expressed using a galactose-inducible promoter).  Since Gpa1 
cannot sequester excess Gβγ (63, 64, 245), the overproduced Ste4Gβ is free to activate 
effectors even in the absence of any stimulus.  As shown in Figure 3.7, knockdown of 
PIK1 dampened Gβγ-mediated activation of Fus3 (Figure 3.7 A and 3.7 C).  Next, we 
overexpressed the constitutively active STE11-4 mutant (190).  STE11 encodes the 
kinase that phosphorylates Ste7, which in turn phosphorylates and activates Fus3 and 
Kss1.  Once again, knockdown of PIK1 dampened STE11-4-mediated activation of Fus3 
(Figure 3.7 B and 3.7 C).  Knockdown of STT4 likewise dampened STE11-4-mediated 
activation of Fus3 (Figure 3.7 E and 3.7 F).  Thus Pik1 promotes signaling by 
pheromone, the G protein, the kinase scaffold, and the protein kinase Ste11. 
Pik1 regulates HOG pathway  
The data presented above indicate that Pik1 regulates the pheromone pathway, 
and that Pik1 acts on, or downstream of, Ste11.  We have largely excluded Ste5 as a 
target for Pik1 regulation, leaving three likely targets: Ste11, its binding-partner Ste50 or 
its direct substrate Ste7 (Figure 3.1 A).  To further distinguish between these candidate 
targets, we examined Pik1 regulation of the HOG pathway (224-226).  The pheromone 
and HOG pathways share the use of Ste11 and Ste50, but not Ste7.  We measured 
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Figure 3.7 
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Figure 3.7  Pik1 acts on Ste11 or a pathway component downstream of Ste11.  
(A) TetO7-PIK1 cells were transformed with pRS315-GAL1-STE4 and grown in 
selective medium containing dextrose or galactose to induce Ste4 (Gβ) protein 
expression. Cells were treated with 10 µg/mL doxycycline for 90 min and 3 µM α factor 
pheromone for 30 min, as indicated. Cell lysates were resolved by 12.5% SDS-PAGE 
and immunoblotting with phospho-p44/42 antibodies (P-Kss1, P-Fus3) and G6PDH 
antibodies as a loading control.  (B) TetO7-PIK1 cells were transformed with pRS425 
(Vector) or pRS425-STE11-4.  (C) P-Fus3 levels from (A) and (B) were quantified by 
scanning densitometry and analyzed with ImageJ software. Results are the mean ± S.E. 
(n=3).  (D) TetO7-STT4 cells treated as in (A).  (E) TetO7-STT4 cells treated as in (B).  
(F) P-Fus3 levels from (D) and (E) were quantified as in (C). 
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activation of Hog1 and Kss1 in response to the addition of 0.5 M KCl.  As shown in 
Figure 3.8, knockdown of PIK1 resulted in diminished Hog1 activity (Figure 3.8 A).  
Furthermore, we again observed constitutive activation of Kss1 as well as an overall 
increase in Kss1 activation in response to salt stress.   
Recent reports indicate that Kss1 activates a Hog1-specific phosphatase Ptp2 
(246).  To determine whether high basal activation of Kss1 was in any way responsible 
for the diminished Hog1 response, we deleted KSS1 from the TetO7-PIK1 strain.  As 
shown in Figure 3.8, the loss of KSS1 did not affect the ability of Pik1 to regulate 
activation of either Fus3 (Figure 3.8 D) or Hog1 (Figure 3.8 C).  Finally, the available 
data indicate that Pik1 and Stt4 act in different ways to promote Fus3 signaling; Pik1 
acts via Ste11 while Stt4 acts via Ste5.  However Pik1 also acts to limit Kss1 signaling.  
As a further test of our model, we monitored Kss1 activity in the absence of Ste11 and 
Pik1 (TetO7-PIK1 ste11Δ strain).  In accordance with the model, we found that Ste11 is 
necessary for the constitutive activation of Kss1 (Figure 3.8 D) while deletion of STE5 
had no effect.  These data further confirm that Pik1 regulates the function of Ste11 but 
not Ste5. 
Discussion 
Signal transduction systems will often share core signaling components yet 
maintain specificity and avoid pathway cross-talk.  In yeast, three proteins have been 
found to preferentially regulate Fus3 and not Kss1.  First, the scaffold Ste5 binds Fus3 
and is required for Fus3 catalytic activity.  Ste5 is not required by other MAP kinases and 
thus helps to differentiate pheromone signaling from other signaling systems.  Second, 
the PtdIns 4-kinse Stt4 promotes activation of Fus3 (but not Kss1), and does so by 
helping to recruit Ste5 to the plasma membrane.  Third, the PtdIns 3-kinase Vps34 
promotes activation of Fus3 in preference to Kss1.  While functionally similar to Stt4 (see  
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Figure 3.8 
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Figure 3.8  Pik1 acts via Ste11.  
(A) TetO7-PIK1 cells were treated with doxycycline for 90 min and 0.5 M KCl for 
the times indicated and analyzed by immunoblotting with phospho-p38 (P-Hog1) 
antibodies, phospho-p44/42 (P-Kss1) antibodies, Hog1 antibodies, or G6PDH antibodies 
as a loading control.  (B) TetO7-PIK1 and TetO7-PIK1 kss1Δ cells were treated with 
doxycycline and 3 µM α factor pheromone for 30 min, as indicated. Immunoblots were 
analyzed with phospho-p44/42, Fus3 and G6PDH antibodies.  (C) TetO7-PIK1 and 
TetO7-PIK1 kss1Δ cells were treated with doxycycline and 0.5 M KCl for 10 min. 
Immunoblots were analyzed with phospho-p38 and G6PDH antibodies.  (D) Wild-type, 
TetO7-PIK1 and isogenic cells carrying ste5Δ or ste11Δ mutations were treated with 
doxycycline and α factor (αF) for 30 min and analyzed with phospho-p44/42 antibodies 
(P-Kss1). All bands were quantified by scanning densitometry and analyzed with ImageJ 
software. Results are the mean ± S.E. (n=3).  
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Figure 3.5), Vps34 is expressed at endosomes rather than at the plasma membrane.  
Here we have investigated the function of another PtdIns 4-kinase Pik1.  Like Stt4, Pik1 
generates PtdIns 4-P and selectively regulates MAP kinase activity.  Like Vps34, Pik1 is 
an endomembrane protein.  Thus Pik1 joins a small but growing number of factors that 
promote MAP kinase signaling specificity.  Unlike any of the previously characterized 
regulators however, Pik1 activates two MAP kinases (Fus3 and Hog1) while 
simultaneously inhibiting a third, competing MAP kinase (Kss1).   
While much has been learned, important questions remain for the future.  For 
instance, is the location of Pik1 at endomembranes related to its unique function in 
signaling?  Activation of intracellular pathways usually requires the assembly of signaling 
components at the plasma membrane.  In pheromone signaling, several mechanisms 
are required to recruit components to activated transmembrane receptors.  The 
heterotrimeric G-proteins subunits Gα  and Gγ (79, 247) and the small G-protein Cdc42 
(248) are covalently modified with lipid moieties that anchor them to the plasma 
membrane.  The scaffold Ste5 translocates from the cytoplasm to the plasma membrane 
by binding to the Gβγ dimer (228) as well as to Stt4-derived PtdIns 4-P and PtdIns 4,5-P2 
(207, 233).  Additionally, the PAK-family kinase Ste20, as well as the closely related 
kinase Cla4, translocates to the plasma membrane by binding both PtdIns 4,5-P2 and 
Cdc42 (249, 250).  Therefore, spatial restriction of signaling components to areas near 
activated receptors helps prevent aberrant activation of parallel pathways.    
Another question is whether Pik1 acts by altering the distribution of some 
signaling protein within the cell.  Our epistasis analysis reveals that the likely target of 
Pik1 is Ste11 or its binding partner Ste50.  Although required for Ste11 catalytic activity, 
the role of Ste50 in yeast MAP kinase signaling is not well understood (225, 251-255).  
Both proteins are shared among three different MAP kinase pathways, and have 
previously been shown to regulate cross-talk between Hog1 and Kss1 (232, 256).  This 
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makes them ideal candidates for regulation of cross-talk between all three pathways.  
Furthermore, Ste11 and Ste50 translocate from the cytoplasm to puncta after exposure 
to osmotic stress (224).  While the puncta were not identified by co-localization with 
known organelle markers, it might be useful to determine if they coincide with the 
distribution of Pik1 or PtdIns 4-P.  While localization studies can be informative, a more 
pressing (and difficult) question is the direct target of Pik1 and PtdIns 4-P.  We consider 
it unlikely that either Ste11 or Ste50 bind to PtdIns 4-P.  Neither protein contains a 
typical phospholipid-binding domain such as a PH or PX domain (169).  However, the 
BLAST CDD database does predict a low confidence BAR (Bin/Amphiphysin/Rvs) 
domain in Ste50 (E-value=0.19).  BAR domains are dimerization, lipid binding, and 
curvature sensing modules found on many proteins involved in protein trafficking (257).  
It is possible this putative BAR domain is responsible for osmotic stress-induced 
localization of Ste11 and Ste50 at puncta, thereby regulating MAP kinase specificity.  
Alternatively, Ste11 and Ste50 could interact with PtdIns 4-P indirectly through 
interaction with a protein containing a known lipid-binding domain.  This model is 
particularly attractive since Ste50 binds the transmembrane protein Opy2, and this 
interaction is required for Ste11 and Ste50 localization at the plasma membrane (255).  
Perhaps an interaction with some auxiliary protein is likewise required for Ste11 and 
Ste50 localization to endomembranes. 
Fus3 is known to down-regulate Kss1 (231).  Thus, a decrease in Fus3 activation 
could lead to elevated Kss1 activation, similar to that observed after PIK1 knockdown.  
While we propose that Pik1 affects a shared upstream component that results in the 
differential regulation of both Fus3 and Kss1, it is possible that Pik1 regulates Fus3 
directly, but Kss1 indirectly.  We consider this unlikely however, since loss of STT4 or 
VPS34 dampens Fus3 activation without a concomitant increase in Kss1 activation.   
Thus, simply dampening Fus3 activation does not result in constitutively-active Kss1. 
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Another question is the mechanism of Pik1 regulation.  Currently, there is little 
evidence to suggest the enzymatic activity of Pik1 is dynamically regulated by 
pheromone.  Garrenton et al. showed that pheromone treatment does not change total 
cellular PtdIns 3-P or PtdIns 4-P levels (75).  Therefore, it is likely that direct regulation 
of an unidentified binding-partner is required.  Interestingly, Hog1 feedback-
phosphorylates Ste50 in response to osmotic-stress and thereby accelerates both Kss1 
and Hog1 inactivation (232, 256).  It is possible that Ste50 phosphorylation affects its 
subcellular localization or its ability to activate Ste11.  We also considered a previous 
suggestion that Pik1 is needed for efficient mRNA export and protein synthesis (75).  
Under conditions where MAP kinase activity is severely affected, however, we observed 
no changes in the expression of control proteins including alcohol dehydrogenase 
(ADH1-RFP), glucose 6-phosphate dehydrogenase, or Hog1 (161).  Furthermore, 
selective knockdown of Pik1 at the Golgi, and not the nucleus, is responsible for 
dampened pheromone signaling (data not shown).  Therefore, Pik1 regulation of MAP 
kinase signaling is likely due to the direct regulation of signaling components present at 
the Golgi membrane.   
In conclusion, we show that Pik1 and PtdIns 4-P promote the activation of Fus3 
and Hog1 while repressing activation of Kss1.  By acting on all three MAP kinases, Pik1 
appears well-positioned to coordinate cellular responses in the face of competing 
signals.  Together with previous demonstrations of signal regulation by a PtdIns 3-kinase 
at the endosome, there is growing evidence for signal coordination by endomembrane-
associated second messengers (65, 258-261).  Finally, Ste11 is homologous to human 
MEKK3 and Ste50 is highly similar to human OSM (Osmosensing Scaffold for MEKK3) 
(262).  Given the conservation of MAP kinase signaling across species, our findings are 
likely to translate to human MAP kinase pathways as well. 
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Experimental Procedures 
Strains, plasmids, and growth conditions - Standard procedures for the 
growth, maintenance, and transformation of yeast and bacteria and for the manipulation 
of DNA were used throughout.  Cells were grown in selective medium containing 2% 
(w/v) dextrose or galactose to induce gene expression.  Yeast strains used are listed in 
Table 3.1.  Plasmids used are listed in Table 3.2.  Plasmid pRS313 GAL-STE5-CTM 
was created by SacI and ApaI digestion of pGS5-CTM (228) and ligation into the 
corresponding sites of pRS313.   
The yeast TetO7 strains (28) were grown in selective medium to A600nm~0.8, re-
inoculated at 1:80 into medium containing doxycycline at a final concentration of 10 
µg/mL and grown to A600nm~0.8.  To activate the pheromone pathway, α factor 
pheromone was added at a final concentration of 3 µM for 30 min unless otherwise 
noted.  To induce osmotic stress, KCl was added to a final concentration of 0.5 M for 10 
min unless otherwise noted.  Time courses were halted by the addition of trichloroacetic 
acid (TCA) at a final concentration of 5%.   
Cell extracts and immunoblotting - Protein extracts were produced by glass 
bead lysis in TCA as previously described (19).  Protein extracts were resolved by 
12.5% SDS-PAGE and immunoblotting with phospho-p44/42 MAPK antibodies (9101L, 
Cell Signaling Technology) at 1:500, Fus3 antibodies (sc-6773, Santa Cruz 
Biotechnology, Inc.) at 1:500, phospho-p38 MAPK antibodies (9211L, Cell Signaling 
Technology) at 1:500, Hog1 antibodies (sc-6815, Santa Cruz Biotechnology) at 1:500, 
and glucose-6-phosphate dehydrogenase (G6PDH) antibodies (A9521, Sigma-Aldrich) 
at 1:50,000.  Immunoreactive species were visualized by chemiluminescent detection 
(PerkinElmer Life Sciences LAS) of horseradish peroxidase-conjugated antibodies (170-
5047 and 170-5046, Bio-Rad Laboratories).  Protein concentration was determined by 
Dc protein assay (500-0112, Bio-Rad Laboratories).  Band intensity was quantified by  
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Table 3.1 Strains Used 
Strain Name Genotype Source 
BY4741* MATa leu2D met15D his3-1 ura3D (263) 
TetO7-STT4 MATa URA3::CMV-tTA kanR-TetO7-TATACYC1-STT4 (28) 
TetO7-PIK1 MATa URA3::CMV-tTA kanR-TetO7-TATACYC1-PIK1 (28) 
TetO7-PIK1 kss1Δ 
MATa URA3::CMV-tTA kanR-TetO7-TATACYC1-PIK1 
kss1::LEU2 This study 
TetO7-PIK1 ste11Δ 
MATa URA3::CMV-tTA kanR-TetO7-TATACYC1-PIK1 
ste11::LEU2 This study 
TetO7-PIK1 ste5Δ 
MATa URA3::CMV-tTA kanR-TetO7-TATACYC1-PIK1 
ste5::LEU2 This study 
vps34Δ MATa vps34::kanR Invitrogen 
*All strains derived from BY4741 
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Table 3.2 Plasmids Used 
Fig Plasmid Name Alias Description Source  
3.1 pRS315 SC-2-013 CEN LEU2 vector (264) 
3.7 pRS425 SC-2-006 2mM LEU2 vector (265) 
3.1 pRS423 FUS1-LacZ SC-2-001 2mM HIS3 PFUS1-lacZ (222) 
3.1 pRS315-STT4 SC-2-075 CEN LEU2 STT4 (161) 
3.1 pRS315-PIK1 SC-2-076 CEN LEU2 PIK1 (161) 
3.7 pRS425-STE11-4 SC-2-025 2mM LEU2 STE11-4 (161) 
3.7 pRS315 GAL1-STE4 SC-2-024 CEN LEU2 PGAL1-STE4 (175) 
3.4 pRS313 GAL1-STE5-CTM SC-2-035 CEN HIS3 PGAL1-STE5-CTM This Study 
 pGS5-CTM SC-2-027 CEN TRP1 PGAL1-STE5-CTM (228) 
3.3 pRS316 STE5-GFPx3 SC-1-055 CEN URA3 GFP-STE5x3-TCYC1 (233) 
3.2 pRS426 GFP-2xPH-PLCδ SC-3-008 2mM URA3 GFP-2xPH-PLCδ (238) 
3.2 pRS426 GFP-2xPH-FAPP SC-3-009 2mM URA3 GFP-2xPH-FAPP (238) 
3.2 pRS416 GFP-Lact-C2 SC-3-010 CEN URA3 GFP-Lact-C2 (239) 
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scanning densitometry using Image J (National Institutes of Health).  Phospho-
Fus3 and phospho-Kss1 values were normalized to G6PDH loading control and 
phospho-Hog1 values were normalized to total Hog1.   
Transcriptional reporter assay - FUS1-LacZ levels were measured 90 min after 
treatment with α factor pheromone using a β-galactosidase assay and fluorescein di-β-
D-galactopyranoside as described previously (209). 
Microscopy - Cells were visualized with differential interference contrast (DIC) 
and fluorescence microscopy using an Olympus Fluoview 1000 confocal microscope 
equipped with a 488 nm laser (blue argon, for GFP).  Images were analyzed using 
ImageJ (National Institutes of Health).   
 CHAPTER IV 
Conclusions and General Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 All figures contributed by Steven D. Cappell 
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Summary 
G protein-coupled signaling pathways have been extensively studied because of 
their role in human disease and their importance as pharmacological targets.  Most 
current drugs target the G protein-coupled receptor, but alternative therapies are being 
developed that modulate G protein signaling downstream of the receptor (5-7).  Thus, a 
complete understanding of the proteins that comprise G protein signaling networks will 
aid in the development of new pharmacological therapies.   
In this thesis, we report the identification of 92 new proteins required for proper G 
protein signaling.  We utilized a repressible-promoter library and quantitative 
transcriptional reporter assays to systematically analyze the essential genes in yeast, a 
group of genes that accounts for ~20% of the yeast genome and has not been 
extensively characterized (62).  Three components of the SCF ubiquitin ligase complex, 
Cdc4, Cdc53, and Cdc34, were among the genes identified in our screen.  We showed 
that the SCFCdc4 polyubiquitinates and regulates turnover of the Gα subunit, Gpa1.  This 
discovery reveals a new mode of regulating G protein signaling via ubiquitination and 
indicates the SCFCdc4 could be a viable drug target.  However, how ubiquitination of 
Gpa1 by the SCFCdc4 is regulated and what is its role in the pheromone pathway remains 
to be determined.   
Also in our screen, we identified two PtdIns 4-kinases, Stt4 and Pik1.  We show 
that both Stt4 and Pik1 are required to maintain MAPK specificity in the pheromone 
pathway, but Pik1, unlike Stt4, also regulates MAPK specificity in the high-osmolarity 
glycerol (HOG) response pathway.  Thus, we defined a novel role for PtdIns 4-P in 
maintaining signaling fidelity in multiple MAPK signaling pathways.  This work reveals 
two new mechanisms that regulate signal transduction, both at the level of the 
heterotrimeric G protein and downstream effectors.  In this chapter, I relate the work in 
this thesis to the existing literature, discuss its implications, and speculate on the future 
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direction of yeast G protein research.   
Role of essential genes in pheromone signaling 
Genes that are involved in critical cellular processes such as transcription, 
translation, and metabolism tend to be essential, and genes involved in dispensable 
cellular processes such as mating tend to be non-essential (27, 62).  Our systematic 
analysis unexpectedly revealed a great deal of overlap between essential genes and 
genes required for proper mating response.  In particular, genes that are involved in 
protein degradation, protein transport, and the cell cycle were over represented in our 
screen, indicating these cellular processes are especially important in both G protein 
signal propagation and cell mating.  
As discussed in Chapter II, genes involved in protein degradation were enriched 
3-fold in our screen.  We demonstrated a role for three such genes, CDC4, CDC53, and 
CDC34, in directly regulating Gpa1 turnover.  However, we also identified 9 other genes 
involved in protein degradation, including 8 components of the 26S proteasome (266, 
267).  This indicates protein degradation must be playing a much larger role in regulating 
the pheromone pathway than just simply regulating Gpa1 turnover.  Indeed, many of the 
components of the pheromone pathway are known to be ubiquitinated, including Ste2, 
Sst2, Gpa1, Ste7, and Ste5 (154, 162, 191, 192).  Still others may await identification.   
Why are so many components of this pathway regulated by ubiquitination?  
There are several potential answers to this question.  First, in the absence of 
pheromone, pathway components are distributed uniformly in the cell.  When cells are 
exposed to pheromone they become polarized and many localize to the tip of the mating 
projection, or shmoo (268, 269).  How these proteins become so polarized is not 
completely understood, but it is possible that ubiquitination may play a role.  In support 
of this hypothesis, pheromone triggers the ubiquitination and internalization of the 
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pheromone receptor Ste2 (162).  Subsequently, newly transcribed Ste2 is delivered to 
the plasma membrane in a polarized fashion to what will eventually become the shmoo 
tip (62, 270).  If ubiquitination of Ste2 is blocked by mutation of its C-terminus, cells are 
unable to polarize and mating is blocked.  This example demonstrates how ubiquitination 
may regulate cell polarization in response to a graded signal, and indicates that other 
proteins in the pheromone pathway may be regulated in a similar fashion.   
Second, ubiquitination may help the cell eliminate signaling components after 
mating has occurred.  When two haploid yeast cells mate, they form a diploid cell.  
Interestingly, many of the components of the pheromone response pathway are not 
expressed in a diploid cell (271).  This likely prevents two diploid cells from mating and 
creating a tetraploid cell.  Thus, immediately following a successful mating event, cells 
must quickly degrade the components of the mating pathway, and the most efficient way 
to accomplish this is through the ubiquitin/proteasome system.  This may explain why 
many ste genes are ubiquitinated. 
In our screen, we also identified many genes involved in protein transport and the 
secretory pathway.  We hypothesize that efficient protein transport is needed to deliver 
newly transcribed signaling molecules to the plasma membrane.  This is certainly true 
for Ste2 and the G protein components, Gpa1, Ste4, and Ste18, which must be available 
at the plasma membrane in sufficient quantities to respond to any pheromone in the 
local environment.  But even after pheromone stimulation, proteins must be delivered to 
the plasma membrane to continue signaling and respond to changing gradients of 
pheromone (272, 273).  For example, in response to pheromone the small G protein 
Cdc42 localizes to the shmoo tip and regulates actin polymerization (274, 275).  Actin 
fibers function to deliver vesicles containing extra membrane material to “build” the 
mating projection and other proteins required for cell-cell fusion.  Cdc42 and actin are 
also important if a cell needs to alter the direction of its mating projection.  Disruption of 
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the protein transport machinery would most likely halt delivery of these key mating 
response proteins and prevent mating.  Thus, our screen of essential genes highlights 
the broad importance of protein transport in maintaining proper signaling.  
Regulation of Gpa1 ubiquitination  
Here we showed that Gpa1 is polyubiquitinated by the SCFCdc4 complex.  
However, it is still not known how Gpa1 ubiquitination is regulated.  Typically, substrates 
of the SCF complex must be phosphorylated in order to bind to the F-box protein.  In 
fact, almost all substrates of F-box proteins identified to date are phosphorylated, 
suggesting that Gpa1 must also be phosphorylated before it can be ubiquitinated (152).  
While there is no substantial evidence so far that Gpa1 is phosphorylated, there is some 
information in the literature that indicates it is.  Two proteome-wide screens of 
phosphorylated proteins in yeast found Gpa1 is phosphorylated on two residues, 
threonine 189 (202) and serine 200 (201).  These data were not confirmed and phospho-
proteomic screens are prone to false positives.  However, these data do indicate that 
Gpa1 may be phosphorylated.  Interestingly, the two proposed phosphorylation sites, 
T189 and S200, are close to the previously identified site of ubiquitination, K169 (158).   
In fact, all three residues are located on the same structurally distinct subdomain, 
specifically a 110 amino acid unstructured region that extends from the all-helical 
domain of Gpa1 (276).   
As discussed in Chapter II, and shown in Figure 2.8F, deletion of the 
ubiquitinated subdomain blocks ubiquitination of Gpa1 by purified SCFCdc4.  This could 
result because the primary site of ubiquitination was deleted.  However, E3 ligases are 
notoriously promiscuous when it comes to choosing a lysine for ubiquitin attachment.  An 
E3 ligase will favor one particular lysine when given a choice, but if that lysine is mutated 
to arginine, the E3 ligase will almost always find a nearby lysine to ubiquitinate (115).  
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Thus, one might expect that despite the deletion of the primary lysine site in the 
ubiquitinated subdomain, the SCFCdc4 would find another site to ubiquitinate, but we 
observed a complete loss of ubiquitination of Gpa1 that lacks the ubiquitinated 
subdomain (Gpa1Δ128-236).  Alternatively, we hypothesize that the 110 amino acid 
ubiquitinated subdomain also functions as the SCFCdc4 binding site when T189 and/or 
S200 are phosphorylated.  In support of this hypothesis, we showed that purified Gpa1 
from E. coli, which should not contain post-translational modifications such as 
phosphorylation, was not ubiquitinated by the SCFCdc4.  Further experiments are required 
in order to make firm conclusions.  Specifically, pull-down experiments should be 
performed between Cdc4 and Gpa1T189A/S200A mutants, Gpa1110Δ mutants, and wild-type 
Gpa1 that has been treated with λ phosphatase.  No interaction between Cdc4 and 
Gpa1 should be detected in any of these three conditions.  However, given that 
phosphorylation of T189 and S200 were identified in phospho-proteomic screens, it is 
possible that there are additional phosphorylation sites on Gpa1, and mutation of T189 
and S200 is insufficient to block binding to Cdc4.  Mass spectroscopy of Gpa1 may be 
required to identify all sites of phosphorylation in order to better understand how Gpa1 
ubiquitination by the SCFCdc4 may be regulated.  
 Cell-cycle regulation of Gpa1 ubiquitination – Gpa1 ubiquitination does not 
seem to be regulated by pheromone.  In early studies of Gpa1 ubiquitination, it was 
thought that pheromone signaling may trigger degradation of Gpa1, providing a 
mechanism whereby signaling could be enhanced or prolonged.  However, experiments 
have shown pheromone does not induce Gpa1 polyubiquitination (159).  Since then, the 
conditions that promote Gpa1 ubiquitination have remained elusive, and it is simply 
thought that a basal level of polyubiquitinated Gpa1 is present in the cell at all times.  
This has prompted the hypothesis that polyubiquitination may be regulating and 
degrading misfolded Gpa1 (159, 160).  However, several pieces of evidence refute this 
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hypothesis.  Most notably, polyubiquitination of Gpa1 has been shown to require 
localization to the plasma membrane.  When the sites of lipid modification of Gpa1 are 
mutated, C2A and C3A, Gpa1 can no longer bind the plasma membrane, and 
surprisingly polyubiquitination is no longer detected in the cell (160).  Replacement of the 
lipid-attachment residues with a polybasic region, Gpa1C2A/4K, restores both plasma 
membrane binding and polyubiquitination.  Only properly folded protein would make it to 
the plasma membrane, suggesting fully formed and properly folded Gpa1 is 
polyubiquitinated.   
We suggest an alternative hypothesis, where Gpa1 polyubiquitination is 
regulated by progression through the cell cycle.  Given that several proteins known to 
regulate the cell cycle, Cdc4, Cdc34, and Cdc53, are directly involved in Gpa1 
ubiquitination, it is likely the cell cycle is involved in regulating Gpa1 ubiquitination.  All of 
the other known substrates of Cdc4, such as Sic1 and Far1, are ubiquitinated in specific 
stages of the cell cycle (152).  To test the hypothesis that Gpa1 ubiquitination is 
regulated by the cell cycle, levels of Gpa1 ubiquitination should be measured in different 
cell cycle stages.  Preliminary experiments conducted by members of our lab using cell 
cycle inhibitors do in fact show that polyubiquitinated Gpa1 is present in G1 but not S or 
G2/M phases (data not shown).  This indicates that Gpa1 is polyubiquitinated and 
degraded in G1 phase, and stabilized in S and G2/M phase.  This correlates well with 
other known Cdc4 substrates, which are also ubiquitinated in G1 (135).  
Regulation of Gpa1 ubiquitination in different cell cycle stages is an attractive 
model because mating is prevented in non-G1 phases of the cell cycle in order to 
prevent aneuploidy.  One mechanism by which this can be achieved is regulating the 
abundance of key signaling components in different stages of the cell cycle (Figure 4.1).  
Since Gpa1 is a negative regulator of pheromone signaling, it is desirable for the cell to  
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Figure 4.1 
 
Figure 4.1 G protein ubiquitination cycle. 
Model showing G protein ubiquitination is regulated by the cell cycle.  In S, G2 
and M phase, Gpa1 is stabilized and prevents activation of the pheromone response 
pathway. Fusion of two cells in any of these phases would result in aneuploidy.  In G1 
phase, excess Gpa1 is ubiquitinated by the SCFCdc4 complex and degraded by the 26S 
proteasome. This restores a more favorable stoichiometry between Gpa1 and Ste4, 
allowing efficient signaling to occur.   
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accumulate Gpa1 in S, G2, and M phases to prevent aberrant signaling.  Then, in G1 
phase, the cell would want to degrade excess Gpa1 to allow greater sensitivity to 
pheromone.  Thus, by regulating Gpa1 levels in different cell cycle stages, the cell can 
fine-tune its ability to respond to mating pheromones.  To test this hypothesis, cells 
arrested in different stages of the cell cycle could be assayed for total cellular Gpa1, 
levels of ubiquitinated Gpa1, and mating efficiency.   Gpa1 could also be purified from 
yeast arrested at different stages of the cell cycle and subjected to in vitro ubiquitination 
assays with SCFCdc4.  Gpa1 purified from cells arrested in G1 should be a suitable 
substrate for the SCFCdc4 while Gpa1 purified from cells arrested in G2/M should not.   
Regulation of total Gpa1 levels – We showed that the SCFCdc4 complex 
polyubiquitinates Gpa1 and targets it for degradation by the 26S proteasome.  Based on 
this knowledge, one would assume that deletion of the SCF complex would result in an 
accumulation of total cellular Gpa1 levels.  However, when we knocked down Cdc4 we 
observed only a slight change in total cellular Gpa1 levels.  There are several 
explanations as to why we did not observe Gpa1 accumulation.  First, we measured 
Gpa1 levels using western blotting, which is a notoriously poor method for protein 
quantification.  The linear range for ECL is rather narrow, which can mask small 
differences in protein concentration.  To better quantify protein levels, we could use a 
secondary antibody fused to a fluorescent probe which has a wider linear range, rather 
then horseradish peroxidase which has a narrow linear range.  Second, small changes 
in Gpa1 are known to have large effects on pheromone signaling.  Gpa1 functions to 
sequester Ste4Gβ, and small increases in Gpa1 levels function to buffer free Ste4 and 
prevent normal pheromone signaling (164).  Thus, the small changes we observed may 
be sufficient to yield a large decrease in pheromone signaling.  Third, we measured total 
cellular protein levels in a population of cells.  This cannot account for variability in the 
population.  Gpa1 levels could be higher in a proportion of cells and unchanged in the 
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rest, masking an accumulation phenotype.  Fourth, western blotting measures total 
protein levels and does not provide any information about subcellular localization.  Given 
that the mating response involves cell polarization, it is reasonable to assume that a 
subpopulation of Gpa1 is targeted for degradation by polyubiquitination.  For example, 
Gpa1 is known to localize to endosomes in small quantities.  It is possible that this small 
pool of endosomal Gpa1 is targeted for ubiquitination and would accumulate in SCF-
deficient cells.  Unfortunately, at this time, we have not had the opportunity to accurately 
quantify Gpa1 levels.  However, the fact remains that depletion of the SCFCdc4 increases 
the half-life of Gpa1 and decreases pheromone signaling, which is rescued by 
overexpressing Ste4Gβ.  Furthermore, Gpa1 is ubiquitinated by the SCFCdc4 in vitro.  
These data provide overwhelming evidence that the SCFCdc4 ubiquitinates Gpa1.   
SCF and disease 
Like other E3s, deregulation of F-box proteins and their ability to recognize 
substrates is often associated with human diseases including cancer and Von Hippel-
Lindau (VHL) disease.  The human homolog of Cdc4, Fbw7, is involved in cancer (277).  
SCFFbw7 degrades several different proto-oncogenes including c-MYC (278), cyclin E 
(151), and c-JUN (279).  Fbw7 is often inactivated by a truncation mutation in breast and 
pancreatic cancer that prevents it from recognizing substrates (280).  Accumulation of 
SCFFbw7 substrates leads to genomic instability and cancer.  Other diseases also involve 
mutated F-box proteins.  VHL is a hereditary disease that results in a predisposition for 
malignant tumors in a number of different organs including the brain, kidney, and 
pancreas.  VHL is caused by a germline mutation in an F-box protein that prevents it 
from recognizing substrates, including hypoxia-inducible-factor (HIF) (281).  HIF controls 
the expression of genes that induce angiogenesis and when overexpressed, supports 
tumor growth by supplying the tumor with a constant supply of glucose and growth 
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factors.  Thus, patients who carry mutations in VHL have elevated levels of HIF, and are 
highly prone to tumor formation (282).  Currently it is unclear how to therapeutically re-
activate mutant F-box proteins that cannot bind substrates such as those found in VHL 
and breast cancer, but this is an active area of research (283).     
 SCFSkp2 also involved in human cancer due to its role in the degradation of the 
cyclin-dependent kinase inhibitor p27 (284).  p27 inhibits cell division and promotes 
quiescence.  Loss of p27 results in unchecked progression through the cell cycle (285).  
Thus, control of p27 levels is required for proper regulation of the cell cycle, and the 
prevention of tumor formation.  When the F-box protein Skp2 is overexpressed in mice, 
p27 levels decrease and tumors start to form (286).  Indeed, Skp2 is found 
overexpressed in many different types of human cancers, and is always correlated with 
low levels of p27 (287, 288).  Drugs that inhibit Skp2 and prevent degradation of p27 
could prove to be a highly successful chemotherapeutics (283, 289).   
 Recently, two labs discovered small molecule inhibitors of F-box proteins (290, 
291).  Aghajan et al. found an inhibitor of the yeast F-box protein Met30, which contains 
seven WD40 repeats and is structurally very similar to Cdc4 (290).  The inhibitor, small-
molecule enhancers of rapamycin (SMER) 3, was found to disrupt binding between 
Met30 and Skp1.  It is hypothesized that SMER3 binds at or near the F-box protein of 
Met30 and prevents its interaction with Skp1.  Interestingly, the authors demonstrated 
that SMER3 was only active with Met30, and not Cdc4.  Thus, despite binding a 
common domain, SMER3 shows remarkable specificity.  Given the role of many F-box 
proteins in human disease (283), these results are encouraging and indicate a common 
mechanism whereby diverse F-box proteins could be inhibited by small molecules.  
 Tyers and colleagues found a small molecule inhibitor of Cdc4 that functions via 
a different mechanism than SMER3.  Using yeast as a model, Orlicky et al. identified a 
small molecule called SCF-I2 that disrupts the Cdc4 substrate-binding domain (291).  A 
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crystal structure of Cdc4 in complex with SCF-I2 shows the small molecule binds 
between two β-propellers formed by WD40 repeats number 5 and 6, and is 25 Å from 
the substrate binding pocket.  By wedging between these two propellers, SCF-I2 induces 
a large conformational shift of the main chain, which disrupts the substrate-binding 
pocket.  Given the high degree of homology between Cdc4 and the human F-box protein 
Fbw7, it is likely that human Gα proteins will also be ubiquitinated by the SCFFbw7.  It is 
our hope that a small molecule similar to SCF-I2 will be found to inhibit Fbw7.  If such a 
drug were developed, it could be used to enhance G protein signaling by stabilizing the 
Gα subunit.  This is an exciting proposition and further reinforces the theory that new 
drugs can be derived from studies of G protein signaling in yeast.   
The crystal structure of SCF-I2 and Cdc4 also indicates a general mechanism 
where all WD40 repeat proteins can be therapeutically targeted.  The list of proteins 
containing WD40 repeats is not restricted to F-box proteins (292-294).  Most notably, the 
Gβ subunit of the heterotrimeric G protein is comprised of 7 WD40 repeats (295, 296) 
and forms the same β-propeller structure as Cdc4 (149, 297).  Perhaps the discovery of 
SCF-I2 could lead to a new class of drugs that directly regulates heterotrimeric G protein 
signaling by disrupting the interaction between Gβ and Gα (298).  Nevertheless, SCF-I2 
and SMER3 prove that small molecule inhibitors of F-box proteins are indeed feasible, 
and future research is likely to focus on F-box proteins involved in human disease, such 
as Skp2 and Fbw7 (289).   
Phosphoinositides in MAPK signaling 
Recently, several reports have detailed new roles for phosphoinositides in 
regulating MAPK signaling pathways.  Specifically, the PtdIns kinases Stt4, Vps34, and 
Pik1 have all been implicated in regulating the pheromone response pathway (65, 75, 
207, 233).  Despite the fact that PtdIns kinases all produce phosphorylated 
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phospholipids, they all seem to regulate signaling via a distinct mechanism.  Stt4 
produces PtdIns 4-P at the plasma membrane and is necessary to recruit the scaffold 
Ste5 to the cell periphery where it can interact with upstream activators such as Ste20 
(207, 233).  This process is required for Fus3 activation but not Kss1 activation.  Vps34 
is localized to early endosomes and produces PtdIns 3-P when stimulated by GTP-
bound Gpa1.  Deletion of VPS34 diminishes Fus3 activation but does not affect Kss1 
activation (65).  The exact mechanism of action of Vps34-derived PtdIns 3-P is not 
currently known.  Pik1 produces PtdIns 4-P at the Golgi and in the nucleus.  Like Vps34, 
knockdown of Pik1 causes a reduction in Fus3 activation.  However, it also causes 
constitutive Kss1 activation.  Thus, in yeast, three separate PtdIns kinases regulate 
MAPK specificity by selectively affecting Fus3 and not Kss1.   
 Although Stt4, Vps34, and Pik1 produce different catalytic products at different 
cellular locations, they all differentially regulate Fus3 and Kss1.  This suggests a general 
requirement for phosphoinositides in maintaining signaling fidelity between multiple 
MAPK signaling pathways that share components.   The most logical hypothesis is that 
phosphoinositides insulate signaling pathways by physically tethering components to 
different subcellular locations.  For example, Stt4 helps tether Ste5, and by association 
Ste11, Ste7, and Fus3, to the plasma membrane in locations of pheromone-bound 
receptors (233).  This most likely helps prevent aberrant activation of Kss1 and a third 
MAPK, Hog1.  Similar mechanisms are likely to exist for Vps34 and Pik1 at endosomes 
and the Golgi respectively.  Examining the localization of proteins that contain lipid-
binding domains could reveal the function of Vps34 and Pik1.   
Proteins can contain a number of different lipid-binding domains including PH, 
PX, ENTH, and FYVE domains (169).  Of these examples, ENTH domain-containing 
proteins are intriguing candidates for proteins that may directly bind phosphoinositides at 
endomembranes and regulate pheromone signaling.  Proteins that contain ENTH 
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domains typically localize to endosomes or the Golgi due to their ability to bind 
phosphoinositides, clathrin coated pits, and possibly actin (299, 300).  Yeast have five 
proteins that contain an ENTH domain, designated Ent1-5 (301, 302).  Ent5 is a 
particularly interesting protein because it is involved in trafficking between the Golgi and 
endosomes (301).  
Ent5 has been shown to physically interact with Fus3 (303).  This indicates Pik1 
and/or Vps34 could be regulating Fus3 activation by physically sequestering Fus3 to 
sites of intracellular compartments through Ent5.  Preliminary data show that Fus3-GFP 
localizes to intracellular puncta in addition to the nucleus (Figure 4.2).  While the identity 
of these spots has not yet been determined, this observation is consistent with the 
hypothesis that PtdIns kinases regulate Fus3 localization to endomembrane 
compartments.   
Genetic studies have also shown a negative interaction between Ent5 and Ste50, 
which is an adapter protein for the MAPKKK Ste11 (304).  Ste50 regulates cross-talk 
between the HOG pathway and the filamentous growth pathway (305).  The genetic 
interaction between Ent5 and Ste50 indicates they function in the same pathway.  
Furthermore, Ste50 localizes to intracellular puncta upon exposure to osmotic stress, 
indicating a physical interaction between Ent5 and Ste50 is possible (176).  It has not 
been determined whether Ste50 localization to intracellular spots is dependent on either 
PtdIns 3-P or PtdIns 4-P.  Nevertheless, the several pieces of evidence outlined above 
suggest Ent5 may be the target of phosphoinositides regulation of MAPK signaling. 
Future experiments should aim at identifying proteins that link phosphoinositides 
to pheromone signaling.  GFP fusions to proteins with known lipid binding domains can 
be monitored in the presence and absence of specific PtdIns kinases.  Candidate genes 
can then be subjected to co-Immunoprecipitation experiments with components of the 
MAPK cascade, specifically Ste50, Ste11, and possibly Fus3.  Ent1-5 will be a high 
122 
Figure 4.2 
 
Figure 4.2  Fus3-GFP localizes to intracellular puncta.  
FUS3-GFP was integrated into the genome of wild-type BY4741 cells. Cells were 
treated with 3 µM α factor for 2 hrs. Cells were visualized and fluorescence microscopy 
using an Olympus Fluoview 1000 confocal microscope equipped with a 488 nm laser 
(blue argon, for GFP).  Images were analyzed using ImageJ (National Institutes of 
Health).   
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priority for analysis, as will other proteins that have physical and genetic interactions with 
known pheromone pathway components.   
Conclusions 
We identified 92 essential genes required for proper pheromone signaling in 
yeast.  Of these, we thoroughly characterized five genes to reveal how they regulate G 
protein signaling.  This work revealed a link between genes that regulate the cell cycle 
via protein ubiquitination and G protein turnover, indicating the cell may control its ability 
to respond to external stimuli by altering the abundance of key signaling components.  
Furthermore, we uncovered new roles for phosphoinositides in regulating fidelity in 
signal transduction networks.  Together, these findings reveal the essential genes are a 
virtually untapped resource for identifying new signaling components.  Given the high 
degree of conservation between yeast and human G protein pathways, discoveries 
made during the course of this research are likely to translate to humans, leading to new 
avenues for drug discovery.    
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APPENDIX I 
PCR Primers (Used In Chapter II) 
Name Primer Sequence 
1 5’-TAG GAT CCG TAG GAA ATA ATG GGG TGT AC-3’ 
2a 5’-TAA AGC TTT GAT TAC AAG GAT GAC GAC GAT AAG AGC CTT TAG CAG 
TAT TCT C-3’ 
3 5’-GAA GGA TGA CGA CGA TAA GAA ACT TAT TCA CGA AGA CAT 
TGC-3’ 4 5’-GCA ATG TCT TCG TGA ATA AGT TTC TTA TCG TCG TCA TCC 
TTC-3’ 5 5’-GGT TGC GTA AAA ATT ATT GAT TTT GGT ATT TC-3’ 
6 5’-GAG CTC GCC ATG TCT AAA GGT GAA GAA TTA TTC ACT GGT G-3’ 
7 5’-GAG CTC GCC ATG TCT AAA GGT GAA GAA TTA TTC ACT GGT G-3’ 
8 5’-CTC GAG CCC GGG GCG AAT TTC TTA TGA TTT ATG ATT TTT ATT ATT 
AAA TAA G-3’ 
9 5’-GAA TTC GGT ACC CAA TAG CAA TGG GGT TTT TTT CAG-3’ 
10 5’-CCC GGG AAC ATG GCC TCC TCC GAG GAC-3’ 
11 5’-CCC GGG GCC TTA GGC GCC GGT GG-3’ 
12 5’-GTC GAC CCA TGC AGA AGC TGT TGC GAA G-3’ 
13 5’-GTC GAC TTT GAT TTT CAG AAA CTT GAT GGC TTA TAT CCT GC-3’ 
Cdc4 F 5’-CAG TTA GAG CTC TGG TAT TCA TCA TCA AAA ACA GCC TTC CAG-3’ 
Cdc4 R 5’-CAG TTA CCC GGG AAA AAT CAG CAG AAT CAA CTT CTT AAC G-3’ 
Cdc34 F 5’-TAG AGC TCG GCA ATT ACT AAT GCG GGT TC-3’ 
Cdc34 R 5’-TAC CCG GGT CGC AAA GAT CGA CCT AAG AC-3’ 
Stt4 F 5’-GAG CTC AAA TTA GGC TGA ATA GAA CTG C-3’ 
Stt4 R 5’-CCC GGG AGA TTT TCC TTG TCC TCC CTT T-3’ 
Pik1 F 5’-CCG CGG CTA GAA GAT ATT GAC ATC GAT TCC G-3’ 
Pik1 R 5’-CCC GGG CGA TGT GCC ATA TAG TAA GCT GG-3’ 
Mps1 F 5’-CCG CGG ATC ACA ACA AAT GGT GAT TCT GG-3’ 
Mps1 R 5’-CCC GGG TCT AAG CAA GAA TGG CAA GAA AG-3’ 
Ste4 F 5’-CAG GTA CAC ATT ACG ATG GAA TTC CAT CAG ATG GAC TCG ATA ACG-
3’ Ste4 R 5’-CGT TAT CGA GTC CAT CTG ATG GAA TTC CAT CGT AAT GTG TAC CTG-
3’ Ste20 F 5’-AAG GAA AAA AGC GGC CGC CTC GCT TAT GGA TTG TGG GAT CTC ACC-
3’ Ste20 R 5’-CCG CTC GAG CCT TTC CGT CAC TGT TCC ATG-3’ 
Ste5 F 5’-TCC CCG CGG GAC ATC AGC TGA TTT CTC ATA GAG-3’ 
Ste5 R 5’-AAG GAA AAA AGC GGC CGC GCT CAT TAT GTA ACC ATT CCG ATT GAC-
3’ Ste11 F 5’-AAG GAA AAA AGC GGC CGC CTG CGC AGC TTT ATA CAA GTT AGC-3’ 
Ste11 R 5’-CCG CTC GAG ACG CTT CTA GAG GTA CAG GCG-3’ 
Ste7 F 5’-CGC GGA TCC TGG TAT CCT TCT TGG GAA TAT TCA ATG C-3’ 
Ste7 R 5’-CCG CTC GAG AGC GAG TAC AGT CAT TGT GTG CCA CC-3’ 
Fus3 F 5’-CGC GGA TCC GCA GCG ACT GCA CTA AAC TAG AGG-3’ 
Fus3 R 5’-CCG GAA TTC TCT AGT AAG ACG GTC TCT TGC TGC-3’ 
Kss1 F 5’-AAG GAA AAA AGC GGC CGC GAC AGA TTA CGA GAG TCC AGC C-3’ 
Kss1 R 5’-CCG CTC GAG CTT GGC TGG GTA TTA GTT GTG-3’ 
Ste12 F 5’-CGC GGA TCC TCT TCC CTT CCC AGA GAG AAA AAA GG-3’ 
Ste12 R 5’-CCG CTC GAG CTG CTT TTA TTA TTT GTT AGT GCC-3’ 
aFLAG sequence highlighted in bold 
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